Epidemiological risk profile of human papillomavirus type 52 infection and its sequence diversity among the general population and cervical cancer patients in Hong Kong. by Ho, Ching Sze. & Chinese University of Hong Kong Graduate School. Division of Microbiology.
Epidemiological Risk Profile of Human 
Papillomavirus Type 52 Infection and Its Sequence 
Diversity among the General Population and 
Cervical Cancer Patients in Hong Kong 
HO, Ching Sze 
A thesis Submitted in Partial Fulfillment of the Requirements 
for the Degree of Master of Philosophy in Microbiology 
©The Chinese University of Hong Kong 
Sep 2007 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a proposed 
publication must seek copyright release from the Dean of the Graduate School. 
h • \ ’ 
• m 1 
XcP I^BRARY 
Declarat ion 
I declare that this thesis represents my own work, apart from the following. 
Cervical samples and clinical data collection were conducted by Dr. Cheung T H, 
Department of Obstetrics and Gynecology; the pathological data obtained from Dr. 
May Yu, Department of Anatomical and Cellular Pathology, and specimen collection 
and conduction of questionnaire were performed by the Shatin Community Cervical 
Screening Clinic under the supervision of Professor Alexander Chang. A l l of the 
experimental works and data analyses were performed by me, unless otherwise stated 
in the thesis. 
Ho Ching Sze 
Date 1 … " f / 叫 
I 
Acknowledgements 
I would like to express my deepest gratitude to my supervisor, Professor Paul K 
S Chan. His wide knowledge and the logical way of thinking have been of great 
value for me. His encouragement, valuable discussion and personal guidance have 
provided a good basis for my study and the present thesis. I am grateful to Dr. 
Raphael Chan, Chairman of our department, for his support of my research. 
I warmly thank Miss Jo Cheung, Research Assistant, for her guidance in 
performing laboratory work and valuable advice during my study. 
I also want to thank Miss Denise Chan and Miss Alana Tarn, former 
postgraduate students of my supervisor, for their excellent works in the previous 
studies, which are essential for me to conduct the current study. 
I am grateful to Professor Alexander Chang, the head of the Shatin Community 
Cervical Screening Clinic, who provided us with the cervical samples and clinical 
data. He also helped conducting face-to-face interview, which provided us 
epidemiological information that is indispensable for this study. 
I am also in debt to Dr. Cheung T H of the Department of Obstetrics and 
Gynecology, who provided us with clinical data that are essential for this study. 
II 
Special thanks to Dr. May Yu of the Department of Anatomical and Cellular 
Pathology, who provided the tumor tissues and pathological data that are 
indispensable for this study. 
I would also like to thank the overseas collaborators, Maria Alejandra Picconi, 
Lucia Giovanni, J S Park, T Y Chu and Y L Woo, for providing us with the 
HPV52-positive samples. 
I wish to thank all labmates and staff in the Department of Microbiology, the 
Chinese University of Hong Kong: Mr. Kam, Alison, Lam, Ida, Apple, Karry, Cheryl 
and the office ladies, for their help and warm encouragements during my study. 
Lastly, and most importantly, I owe my loving thanks to my parents and family 
for their love and support. I warmly thank Jason Cheung for his love, encouragement 
and patience. Thank you for the emotional support and caring provided. Without 
their encouragement and understanding it would have been impossible for me to 
finish this work. 
Part o f the study was supported by a donation from GlaxoSmithKline Limited, 
Hong Kong. Special thanks to Mrs. Rachael Fan and Ms. Margaret Cheung for their 
support and enthusiasm in improving women health. 
Ill 
Abstract of thesis entitled 
Epidemiological risk profile of human papillomavirus type 52 infection and 
its sequence diversity among the general population 
and cervical cancer patients in Hong Kong 
Submitted by 
Ho Ching Sze 
for the Degree of Master of Philosophy 
at the Chinese University of Hong Kong 
in Sep 2007 
Cervical cancer is the second most common cancer in women worldwide, and 
ranks fifth in Hong Kong. It is widely accepted that human papillomavirus (HPV) 
infection plays a central role in the aetiology of cervical cancer. 
The prevalence and genotype distribution of HPVs among 2604 Chinese women 
enrolling for a Pap smear at the Shatin Community Cervical Cancer Screening 
Centre were examined by PGMY09/11 PCR and reverse line-blot hybridization. 
Interview was conducted to determine their epidemiological characteristics, and the 
risk association was analyzed using multiple logistic regressions. The overall 
prevalence of HPV in Hong Kong Chinese population was 6.7%. HPV 16 (1.2%), 52 
(1.2%) and 58 (1.2%) being the three most prevalent HPV types, respectively. The 
IV 
age-specific prevalence of HPV infection peaked at the age group of 26-30 years, and 
a minor peak was observed in elder women of age 46-55 years. It was found that 
young age was associated with an increased prevalence for HPV infection of all 
types, except for the low-risk HPV groups. Smoking behavior, both active and 
passive, had an independent risk association with HPV infection. Number of lifetime 
sex partners was associated only with low-risk HPV infection. History of treatment 
for cervical lesions was positively associated with any-type and high-risk HPV 
infection. Number of full-term pregnancies, age at first sexual intercourse, use of 
barrier contraception and oral contraception did not have independent association 
with HPV infection. 
Unlike other geographic regions, HPV52 was more prevalent in Hong Kong, 
which led to the study on HPV52 sequence variation and its correlation with the 
development of cervical cancer and precancer. A total of 132 Hong Kong subjects 
with HPV52 infection had been identified and examined. A total of 45 samples that 
were known to have HPV52 were contributed by overseas collaborators. HPV52 E6, 
E7, L I open reading frames and LCR were sequenced. The HPV52 prototype 
(GenBank accession number: X74481) was used as the reference for comparison. 
The L I region was found to be most conserved among the four regions examined. 
HPV52 E7 was found more variable than E6, as in contrast to HPV 16. Of the Hong 
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Kong isolates, 6.8% HPV52 prototype-like variants were found. A higher risk for 
cervical cancer of HPV52 E6 N122K variant with the P-value of 0.009 by the 
Fisher's exact test was observed. Six novel amino acid substitutions: L5S, P122A, 
P203L, N207T, K423T and R529K within the L I open reading frame were found. A 
lower risk for cervical intraepithelial neoplasia I I I and invasion cancer was observed 
for the L I prototype-like variants with an odds ratio of 0.09 (95% confidence interval 
=0.00-0.86). HPV52 LCR variants with one or more nucleotide changes impacting 
the putative Oct-1 binding site at nt7933-7945 showed a protective effect against 
invasive cervical cancer with an odds ratio of 0.14 (95% confidence interval 二 
0.03-0.61). Further study on the functional implications of high- or low-risk amino 
acid substitutions in HPV52 variants revealed in this study is warranted. 
No HPV52 prototype-like variant was found from the Taiwanese, Korean and 
Argentinean isolates. HPV52 prototype-like variants were found in the only 
Canadian isolate, three out of four of the Italian and three out of eight of the UK 
isolates. However, the pathology status for 12 of the overseas samples was not 
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1.1 Biology of human papillomavirus 
1.1.1 History 
Warts in animals and humans were proved to be caused by infectious agents in 
the 1890's. However, human papillomavirus (HPV) was only reported in 1949 as the 
virus that causes these diseases (Strauss et al., 1949). 
Before the development of cloning techniques, study on the biological 
properties of human papillomavirus was very limited, as it was difficult to culture the 
virus in laboratory settings. Raft culture and xenograft models (Howett et al., 1990, 
McCance et al., 1988) were developed in late 1980's, but still did not result in great 
breakthrough. 
With the advent of molecular cloning techniques in the 1970,s, nucleotide 
sequence based analysis could be performed. HPVl was the first HPV full genome to 
be available (Danos et al., 1982). In 1985, the complete genome of the oncogenic 
HPV 16 was sequenced (Seedorf et al., 1985). To date, more than 200 HPV types 
have been detected and more than 100 of them have been well characterized 
(Vasiljevic et al., 2007). 
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1.1.2 Classif ication 
Human papillomaviruses were initially classified along with polyomaviruses 
under the family Papovaviridae, as both of these viruses have similar non-enveloped 
capsids and circular double-stranded DNA genomes. In 2004, papillomaviruses were 
classified by the International Committee on the Taxonomy of Virus (ICTV) as an 
individual family, Papillomaviridae, including all human papillomaviruses and 
papillomaviruses infecting other animal species (de Villiers et al., 2004). 
Previously, the classification of papillomavirus was based on the sequence 
variation of the E6, L I and long control region (LCR). At present, the classification 
of papillomavirus is based on the sequence variation of the L I open reading frame, 
which is the most conserved region within the genome. An isolate is defined as a new 
HPV type i f the sequence of L I open reading frame differs more than 10% from the 
closest known HPV type. Difference between 2% to 10% is defined as a subtype, and 
differences less than 2% is defined as a variant. 
De Villiers (de Villiers et al., 2004) further modified the existing classification 
scheme by introducing the terms genus and species. The sequence of the L I open 
reading frames of 96 human papillomavirus types and 22 animal papillomaviruses 
were compared; isolates that share less than 60% nucleotide sequence similarity 
3 
within the L I open reading frame were classified into different genera. Species 
wi th in a genus share 60-70% o f sequence similarity, whereas types within a species 
share 71-89% of sequence similarity which is in line with the traditional 
classification. Under this classification, 16 genera have been identified, and most o f 
the human papillomaviruses are within the alpha-, beta-, gamma- and 
delta-papillomavirus genera. 
Human papillomaviruses can also be classified according to their site of 
infections as genital or non-genital types, or classified according to the cell types at 
which the infection takes place. HPVs that affect cutaneous type of skins, for 
example the skin of hands and feet are termed cutaneous HPV. Those affecting 
mucosal epithelium such as the lining of the mouth, respiratory tract or anogenital 
epithelium are termed mucosal HPV. 
Genital HPVs are also classified into high-risk and low-risk types according to 
their association with cervical cancer (Cogliano et al., 2005, Munoz et al., 2003). 
HPV types 16，18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 were categorized as 
high-risk types; HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108 were 
categorized as low-risk types 
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1.1.3 Genome structure 
Human papillomavirus is a nonenveloped virus of 55 nm diameter in size. The 
nucleocapsid is o f icosahedral symmetry, which is composed of 72 capsomers and 
about 12 minor capsids protein, L2. Each capsomer contains a pentamer of the major 
capsid protein, L I . HPV consists of a single circular double-stranded DNA genome 
of about 7900 bp associated with histories. A l l open reading frames (ORFs) are 
transcribed in a single direction. The genome is divided into three parts, the 
non-coding long control region (LCR) and the coding early (E) and late (L) regions. 
The early region encodes six early genes, E l , E2, E4, E5, E6 and E7 responsible for 
viral replication, transcriptional regulation and oncogenesis; whereas the late region 
contains two late genes, L I and L2 encoding the viral structural proteins. (Figure 1.1) 
The early genes E3 and E8 encode E3 and E8 proteins, which were found in bovine 
papillomaviruses, but not in HPV; and the function of these proteins are unknown. 
The non-coding region, referred to as LCR or upstream regulatory region 
(URR), is 400-850 bp in length. It is positioned between the L I and E6 genes and 
contains most o f the elements that regulate transcription. A l l the early and late genes 
are transcribed uni-directionally from the promoter located in the LCR or in the E6 
and E7 genes. The LCR is divided into 5'-LCR, central LCR and 3'-LCR. An 
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enhancer is located in the central LCR at about 400 bp upstream of the E6 promoter 
(Cripe et al., 1987, Swift et al., 1987), where a number of transcription factor binding 
sites, such as AP-1, NF1,C/EBP and Oct-1 can be found. 
The early genes, E l and E2 encode proteins responsible for viral replication and 
transcriptional control. E l protein binds to the viral origin o f replication in the long 
control region and process helicase activity for DNA replication (Hughes and 
Romanos, 1993), while the E2 protein facilitates the binding of E l to the viral origin 
of replication (Dixon et al., 2000) and ensures the distribution of viral genomes to 
each daughter cell after cell division (McBride et al., 2004). E2 also acts as the 
transcriptional regulator and serves as a negative regulator of expression of E6 and 
E7 oncogenes (Dowhanick et al., 1995). The functions of E4 protein are not fully 
known, it is thought to facilitate virion release into the environment by disrupting 
intermediate filaments of the keratinocyte cytoskeleton. 
E5 is not present in all HPVs, and it has been suggested that E5 interacts with 
the epidermal growth factor (EGF) and perform transforming activity in some HPV 
types such as HPV 16 (Straight et al., 1995). HPV E6 and E7 proteins act as 
oncoproteins and interact with several cellular proteins. E6 causes degradation of the 
tumor suppressor protein p53 and activates telomerase (Huibregtse et al., 1991), 
6 
while E7 inactivates pRB and allows productive replication in differentiated cells 
(Chellappan et a l , 1992). 
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Figure 1.1 HPV genome structure 
LCR, long control region; E, early gene; L, late gene. 
Modified from: Cervix cancer screening. Lyon, lARCPress, 2005 ( lARC Handbooks of Cancer 
Prevention, Vol. 10). 
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1.1.4 Life cycle 
Human papillomaviruses are highly species-specific. They infect epithelial cells, 
and they are dependent on differentiation of epithelial cells for completing their life 
cycle. Initial infection takes place in the basal layer o f epithelial cells, where the 
HPV genomes then exists as episomes in the nucleus with approximately 50-100 
copies per cell. As the infected cells divide, viral DNA is distributed between 
daughter cells. The maintenance of the viral DNA as an episome is by the expression 
of viral E l and E2 proteins (Wilson et al., 2002), which also ensure the correct 
segregation of genomes during cell division (You et al., 2004). In normal epithelia, 
basal cells exit the cell cycle soon after migrating into the suprabasal cell layers and 
undergo terminal differentiation (Madison, 2003). However, in infected epithelia, the 
expression of E6 and E7 block the cell cycle exit, which allow the differentiated 
suprabasal cells to undergo S-phase in order to replicate HPV genomes (Fehrmann 
and Laimins, 2003). In the upper layers of epithelia, the late promoter is up-regulated 
and leads to increased expression of E l , E2, E4 and E5 genes, which increase the 
genome amplification (Fehrmann and Laimins, 2003, Ozbun and Meyers, 1998). The 
structural proteins, L I and L2 are expressed in the upper layers resulting in the 
reassembly of infectious virions. The virions are released into the environment via 
the desquamation of the epithelia. 
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There is evidence for the existence of latent phase of HPV infection. HPV 16 
DNA has been frequently detected in the cervical tissue of women without clinical 
symptom. Papillomas consistently and rapidly recur in patients suffering laryngeal 
papillomatosis even after laser treatment CFerenczy et al.. 1985)，suggesting the 
presence of latent stale. In this state, only very few papillomavirus DNA remain in 
the basal epithelia. which can be reactivated when the levels of immunosun eillance 
decline (Zhang et al.. 1999). However, the question on whether latency really exists 
requires more investigation. 
1.2 Epidemio logy of cervical cancer 
1.2.1 Cervical intraepithelial neoplasia and cervical cancer 
Cervical cancer is a continuous disease process progressing gradually from mild 
cervical intraepithelial neoplasia to more severe degrees of neoplasia and finally to 
invasive cancer, i f remained untreated (Holowaty et al” 1999) (Figure 1.2). 
There are two main types of cervical cancer, squamous cell carcinoma arising 
from squamous epithelium and adenocarcinoma arising from the gland bearing 
epithelium of the cervical canal. Squamous cell carcinoma cover nearly 90% of the 
cervical cancer (Schiffman, 1994), most of the squamous cell carcinoma are 
10 
developed in the squamous-columnar junction of the transformation zone, where 
columnar endocervical-type epithelium is replaced by a stratified squamous 
epithelium in the process called squamous metaplasia. 
11 
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1.2.2 Spectrum of cervical neoplasia 
Cervical intraepithelial neoplasia (CIN) is the pre-cancer stage of cervical 
cancer. The CIN system is the histological classification of cervical cells dysplasia, 
which was introduced in late 1960's (Richart, 1973). Under this system, mildly 
abnormal cells are classified as CIN I, moderately to severely abnormal cells are 
classified as CIN I I or III, and finally cancer (Figure 1.3). 
In 1988, the Bethesda system was developed based on the cytological 
abnormalities. It was amended in 1991 (Broder, 1992) and further modified in 2001 
(Solomon et al., 2002). Under the Bethesda System 2001, squamous cell 
abnormalities are classified into four categories, ASC (atypical squamous cells), 
LSIL (low-grade squamous intraepithelial lesions), HSIL (high-grade intraepithelial 
lesions) and squamous cell carcinoma. ASC includes cells that have cellular 
abnormalities suggestive of squamous intraepithelial lesions, and includes atypical 
cells that cannot exclude HSIL; LSIL includes mild cervical intraepithelial dysplasia 
and other HPV-associated lesions generally considered to be due to transient HPV 
infection; HSIL consists of moderate and severe cervical intraepithelial dysplasia and 
carcinoma in-situ. 
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CIN, cervical intraepithelial neoplasia grade I, II or III. 
Adapted from: Comprehensive cervical cancer control: A guide to essential practice. Switzerland, 
WHO, 2006. 
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1.2.3 Incidence of cervical cancer 
Cervical cancer is the second most common cancer among women worldwide 
after breast cancer, with estimated 471 000 new cases and 233 000 deaths in the year 
2000 (Parkin et al., 2001). Almost 80% of the cases are occurring in the developing 
countries in South America, sub-Saharan Africa and South and South-east Asia. 
Cervical cancer accounted for 15% of all new cancer cases in the developing 
countries, compared to 4% of all cancer cases among women in developed countries. 
The high prevalence of cervical cancer in developing countries is mainly due to the 
lack of screening programme, as we look back to 1960’s before the introduction of 
screening programmes, the pattern of cervical cancer rates was similar to that of the 
developing countries today (Gustafsson et al., 1997). 
Cervical cancer ranked fifth among all the cancer cases in women in Hong 
Kong after breast, colorectum，lung and corpus cancer. There were 439 new cervical 
cancer cases registered in the year 2004 according to the Hong Kong Cancer Registry, 
which accounted for 4.3% of all new cancer cases in women. Mortality rate of 
cervical cancer ranked eighth among all deaths in women caused by cancers, a total 
of 128 deaths were registered in 2004 (Hong Kong Cancer Registry, 2007). 
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1.2.4 Screening programme 
Papanicolaou-stained (Pap) smear is the primary screening method for 
detecting abnormalities in cervical cells. This method is named after George 
Papanicolaou, who refined the technique of conventional cytology and demonstrated 
its use in identifying precancerous lesions of the cervix (Papanicolaou, 1949). The 
introduction of cytology screening allows cytologists to identify women with 
cervical precancerous lesions, who maybe at risk of progressing to invasive cancer, 
thus appropriate treatment can be performed to prevent further development into 
cervical cancer. 
Performance of conventional Pap smear was evaluated in various large-scale 
studies. Some studies reviewed that the specificity and sensitivity of cervical 
cytology were unsatisfactory, with sensitivity ranged from 30% to 87%, and 
specificity ranged from 86% to 100% (Fahey et al., 1995, McCrory et al., 1999, 
Nanda et al., 2000). However, other studies observed a high specificity of 96-98%, 
with sensitivity of more than 70% (Cuzick et al., 1999, Denny et al., 2000). 
In spite of the controversy on the efficacy of Pap smear screening, its 
effectiveness in reducing cervical cancer is proved. After the introduction of Pap 
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smear screening, the cervical cancer incidence and mortality rate was reduced by 
about half to two-thirds (Kurman et al., 1994). In the United Kingdom, a 
wide-coverage, organized cervical cancer screening programme was introduced only 
in 1988, and a sharp decrease in cervical cancer incidence and mortality rate was 
already observed since 1990 (Gibson et al., 1997, Sasieni et al., 1995). 
1.3 Risk factors for cervical cancer 
It is widely accepted that human papillomavirus infection plays the central role 
in the aetiology of cervical cancer (Munoz et al., 1992). However, only a little 
proportion of women who have been infected with HPV progressed to cervical 
cancer, thus, HPV infection alone is not sufficient for cancer development. 
Epidemiological studies conducted during the past 30 years indicate that the risk for 
cervical cancer is associated with the number of sexual partners, age at first sexual 
intercourse, smoking behaviour, use of oral contraceptives, number of parity, diet 
and history of sexually transmitted diseases. 
Long-term use of oral contraceptives was found to have a higher risk for 
cervical cancer. A meta-analysis study reviewed a linear dose-response relationship 
of cervical cancer with hormonal contraceptives. The odds ratio (OR) was 1.3 for 
women taking oral contraceptives for five to nine years; for women taking 10 or 
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more years of oral contraceptives, the odds ratios raised to 2.5 (Smith et al., 2003). 
Another case-control study reviewed that the risk for adenocarcinoma was also 
increased with increasing years of using hormonal contraceptives (Castellsague et al., 
2006). 
High parity was also associated with cervical cancer, the odds ratio of women 
who gave five or more births varied from 3.8 (Munoz et al., 2002) to 4.4 (Parazzini 
et al., 1989). In a population-based study in Finland, risk for cervical cancer and 
cervical intraepithelial neoplasia for women with at least five children was 
investigated. It was found that young age at first birth was associated with an 
increased risk for both cervical cancer and CIN III, while further increase in parity 
from five to eight had no effect (Hinkula et al., 2004). 
The significant association between smoking and cervical cancer have been 
reviewed in studies worldwide. Increased risk for cervical cancer among 
HPV-positive women who smoked was observed with an odds ratio of 2.17 (Castle 
et al., 2002), showing that smoking was associated with cervical cancer even after 
adjusted for the strong effect of HPV infection. Smoking women were found to carry 
HPV infections longer (Giuliano et al., 2002), and the detection of nicotine and 
tobacco-specific carcinogens in the cervical mucus of smokers (Prokopczyk et al., 
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1997) provided the evidence for the synergistic action between cigarette smoking and 
HPV infection for the development of cervical cancer. 
There were a number of studies suggesting the role o f diet and nutrition on the 
risk for cervical cancer. However, the epidemiological evidence supporting an 
association between diet and nutritional status and cervical carcinogenesis remains 
inconclusive (Garcia-Closas et al., 2005). There was one most relevant new findings 
of the possible protective effect of fruits and vegetables on HPV persistence (Sedjo et 
al., 2002). It was found that low intake of vegetables was associated with HPV 
persistence. Folate was found to have a probable protective effect for cervical 
neoplasia, which showed a strong protection of plasma folate for CIN I - I I I 
HPV-positive women (Kwasniewska et al., 1997), and lower levels of antioxidants, 
such as retinol, alpha-tocopherol, vitamins C and vitamins E coexisting with low 
levels of folic acid increases the risk of CIN development. 
Sexual behaviours like the number of sexual partners and the age of first sexual 
intercourse were linked to increased risk for cervical cancer (Green et al., 2003, 
Svare et al., 1998). However, among HPV-exposed women, the number of lifetime 
sexual partners and the age of first sexual intercourse were no longer associated with 
cervical cancer, illustrating that the increased risk of cervical cancer associated with 
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sexual behaviour was largely confounded by the exposure to HPV (Shields et al., 
2004，Thomas et al., 2002). 
Harald zur Hausen was the first to propose that herpes simplex virus type 2 
(HSV-2) and HPV act together to induce cervical cancer (zur Hausen, 1982). 
Hildesheim et al. compared women with HSV-2 and HPV 16/18 infections with 
women negative for both infections. They found that infection with HSV-2 alone had 
a relative risk of 1.2, women infected with HPV 16/18 DNA had a relative risk of 4.3 
(95% confidence interval = 3.0-6.0), while women that were positive for both HSV-2 
and HPV 16/18 had a relative risk of 8.8 (95% confidence interval = 5.9-13.0), which 
suggested the possibility o f HSV2 as a cofactor in HPV carcinogenesis (Hildesheim 
et al., 1991). An increasing risk for cervical cancer associated with increasing 
number of genital infections was also observed (Schmauz et al., 1989). Pooled 
case-control analysis by the International Agency for Research on Cancer ( lARC) 
showed that there is a 1.5- to 2-fold increase in risk for cervical cancer with HSV-2 
and C. trachomatis infection (Smith et al., 2002,Smith et al., 2004), which provided 
more evidence on the association of cervical cancer and genital tract infections. 
1.4 Oncogenic HPV infection 
The link between HPV infection and cervical cancer was first demonstrated by 
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Harald zur Hausen in 1980，s (zur Hausen, 1987). The association between HPV and 
cervical cancer has been evaluated again recently (Bosch et al., 2002). It was 
concluded that the evidence available now is consistent that HPV infection is the 
necessary cause of cervical cancer. 
1.4.1 Risk association 
A previous study by the International Biological Study on Cervical Cancer 
( IBsee) investigated invasive cervical cancer samples from 22 countries and found 
that the HPV prevalence in cervical cancers was 93% (Bosch et al., 1995). 
Walboomers et al. reanalyzed the negative samples from the IBSCC study by 
applying more sensitive methods. They found that HPV DNA was present in 
virtually all invasive cervical cancer samples (99.7%), which provided a strong 
evidence for the association of HPV and invasive cervical cancer. In that study, three 
sets of PCRs were performed instead of using PGR for L I open reading frame alone 
to avoid false-negative results due to the loss of HPV L I upon integration of the viral 
genome; a sandwich technique was used to assess the formalin-fixed, 
paraffin-embedded biopsies to prevent false-negative results due to the absence of 
cancer cells in the piece of sample under investigation (Walboomers et al., 1999). 
Munoz et al. pooled data from 11 case-control studies from nine countries 
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involving 1918 squamous-cell cervical cancer cases and 1928 controls. The HPV 
prevalence for squamous cell carcinoma was found to be 96.6%, and the overall HPV 
odds ratio for squamous cell carcinoma was 158.2 (95% confidence interval of 
113.4-220.06), which revealed the strong association of HPV and squamous cell 
carcinoma. It was found that the HPV type-specific odds ratios for squamous cell 
carcinoma of the high-risk HPV types ranged from 45.1 to 434.5. The odds ratios for 
HPV 16, 59 and 33 was 434.5, 419.2 and 373.5, respectively (Munoz et al., 2003). 
From another study on cervical adenocarcinoma, 93% of the samples were positive 
for HPV and the odds ratios for HPV 16, 18, 33 and 45 was 164.1, 410.3, 117.4 and 
47.1, respectively (Castellsague et al., 2006). 
Studies showed that the duration of infections for high-risk HPV types were 
much longer than that of low-risk HPV types (Franco et al., 1999,Woodman et al., 
2001). A number of prospective follow-up studies on women with or without cervical 
abnormalities revealed that the continuous presence of high-risk HPV is necessary 
for the development, maintenance and progression of cervical intraepithelial 
neoplasia (Koutsky et al., 1992,Nobbenhuis et al., 1999). 
These studies provided evidence for the aetiological association between HPV 
infection and the development of cervical cancer. 
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1.4.2 Geographical distribution 
Clifford et al. pooled data from 85 studies in 22 countries involving 10 058 
cervical cancer cases. It showed that most of the cervical cancer cases were 
associated with high-risk HPV types, of which, HPV 16 and 18 accounted for more 
than 75% of invasive cervical cancer worldwide. In that study, HPV 16 (51 %) was the 
most prevalent type found worldwide, followed by HPV 18 (16.3%), 45 (4.4%), 31 
(3.9%), 33 (3.8%), 58 (2.7%) and 52 (2.3%). The ranking of HPV types showed 
some variations among different geographic regions, for example, the prevalence for 
HPV52 (4.2%) and 58 (5.4%) were much higher in Asia, which ranked forth and 
third, respectively (Clifford et al., 2003). Nevertheless, HPV 16 and HPV 18 remained 
as the two most prevalent types. 
Data on cervical adenocarcinoma showed a similar pattern of type-specific 
prevalence worldwide, with HPV 16 and 18 being the two most prevalent types, 
followed by HPV45, 59 and 35 respectively (Castellsague et al., 2006). However, a 
higher prevalence of HPV 18 was observed in adenocarcinoma than in squamous cell 
carcinoma. HPV 18 was found in 39% of adenocarcinomas, compared to 18% of 
squamous cell carcinoma. In a few studies, HPV 18 was shown to be predominant 
over HPV 16 (Clifford et al., 2003, Zielinski et al., 2003). 
Studies showed that HPV52 and 58 were more commonly found in invasive 
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cervical cancer in China and Hong Kong than other areas. In Shanghai, Guangzhou, 
Sichuan, Beijing and Honk Kong, HPV58 (3.8%) and 52 (2.6%) ranked the third and 
forth most common genotypes (Lo et al., 2002). In Hong Kong, the prevalence of 
HPV52 (5%) and 58 (7%) was just below HPV 16 and 18 (Chan et a l , 1996). A study 
from Shenzhen city of China showed that HPV52 was the most common type, 
followed by HPV 16 and 18, among women with cervical intraepithelial neoplasia I 
or above (Wu et al., 2007). Higher prevalence of HPV52 and 58 was also observed in 
other Asian countries, such as Taiwan, Japan and South Korea (Maehama et al., 2002, 
Pao et al., 1993, Shin et al., 2003). High prevalence for HPV58 was also observed in 
a non-Asian country, Brazil, which ranked second after HPV 16 among women with 
cervical lesions (Camara et al., 2003). 
1.4.3 Age distribution 
The prevalence of HPV infections was highest among young women at the peak 
of sexual activities. In a two-year cohort study on female university students, 53% of 
students were found having an HPV infection in at least one of the visits (Richardson 
et al., 2005). This study demonstrated the high exposure to HPV among young 
sexually active women. 
Different age-specific curves of HPV prevalence were observed in different 
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areas over the world. However, the highest prevalence was consistently found in 
young women of age below 25 years (Franceschi et al., 2006). A U-shaped pattern 
was observed in Chile, Colombia and Mexico, where a first peak was observed in 
younger women (<25years old) and gradually declined, then, a second peak of 
prevalence was observed in elder women (>55 years old). Netherlands and Vietnam 
showed a much higher prevalence in younger women and then declined to lower 
level. Other countries like Italy and Spain showed a linear decline in HPV prevalence 
with increasing age. 
1.4.4 Oncogenic property of HPV 
The role of E6 and E7 genes in HPV-associated carcinogenesis is well 
established. The E6 and E7 genes of high-risk HPV types, such as HPV 16 and 18 
have been confirmed as oncogenes, and process transforming ability (Munger and 
Howley, 2002) (Figure 1.4). 
The key activity of high-risk E6 protein as an oncoprotein is the ability to 
inhibit the function of p53 (Werness et al., 1990). p53 is a tumor-suppression protein 
responsible for DNA repair and apoptosis. It mediates G1 arrest in damaged cells via 
the induction of p21 gene, which encodes an inhibitor of cyclin-dependent kinase and 
leads to cell cycle arrest and apoptosis. The high-risk E6 protein binds to a cellular 
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protein, E6AP and enhances its interaction with p53, which leads to the rapid 
ubiqutin-dependent degradation of p53 (Huibregtse et al., 1991), thus allowing the 
progression of cell cycle. E6 can also activate cellular telomerase in differentiated 
cells and increase its life span by preventing telomere shortening (Mantovani and 
Banks, 2001). 
E7 protein induces cell proliferation through its interaction with cellular 
proteins of the pRB family such as pRB, p i07 ad pi30. pRB is a negative regulator 
of cell cycle at the Gl /S boundary. In normal cell, hypophosphorylated pRB binds to 
E2F-1 and prevents its action. In response to growth-promoting signals, it is 
phosphorylated by cyclin-dependent kinase and loses its ability to bind E2F-1. E2F-1 
is then released and is able to transactivate genes for cell-cycle progression. In the 
presence of E7 proteins, E7 binds to pRB and displaces E2F-1 from pRB, allowing 
the cell cycle to progress to S phase in the absence of growth-promoting signals 
(Chellappan et al., 1992) and allow the amplification of viral DNA. It has been 
shown that both low-risk and high-risk HPVs are able to bind pRB. However, the 
pRB-binding affinity of low-risk types was much lower than high-risk types (Munger 
et al., 2001). 
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Not all HPV types contain E5. The E5 open reading frame was found to be 
deleted in cervical cancer cells suggesting that it is not essential for the maintanence 
of carcinogenesis property (Schwarz et al” 1985). However, some studies indicated 
that it also processes weak transforming activity in HPV 16 (Crusius et al., 1997). 
E2 is a negative regulator for E6 and E7 expression, transient over-expression of 
E2 proteins results in suppression of E6 and E7 expression and re-activation of the 
normal function of p53 and pRB (Goodwin et al., 1998). However, in some cervical 
cancer samples, viral genome was found integrated into the host genomes, causing 
the disruption of E l and E2 genes. It is also found that most o f the HPV 18 induced 
cervical cancer was associated with viral genome integration, while the viral genome 
of HPV 16 existed as the mixture of integrated and episomal form (Badaracco et al., 
2002). The loss of E2 genes in cancer cells elevated the expression of E6 and E7 
oncogenes as a result of the release of the E2-mediated negative control, and thus 
exert a growth advantage on the infected cell, allowing its continuous proliferation 
(zur Hausen, 2000). 
1.4.5 Sequence variation 
Genital HPVs were classified into low-risk and high-risk types according to 
their association with cervical neoplasia and cancer, and the oncogenicity of variants 
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of the same types also varied. Most of the studies on viral genes were related to E6 
gene on HPV 16, which accounted for more than 50% of the cervical cancer 
worldwide (Clifford et al., 2005). 
Many of the studies have found a higher risk o f progression to cervical cancer 
for non-European HPV 16 variants than European HPV 16 variants (Berumen et al., 
2001, Hildesheim et al., 2001, Vil la et a l , 2000, X i et al., 1998). However, infection 
with Asian HPV 16 variants did not show a higher risk for cervical cancer compared 
to infection with European variants in Hong Kong Chinese (Chan et al., 2002b), 
which suggested that instead of classifying variants into European and non-European 
groups, a finer comparison should be adopted to reveal their differences in the risk of 
developing cervical cancer. 
One of the European variants, T350Q results in L83V amino acid substitution in 
E6 protein was frequently found in cervical intraepithelial neoplasia and cervical 
cancers, and was found to associate with higher progression rate (Kammer et al., 
2002, Zehbe et al., 2001). The higher association of this variant to cervical cancer 
progression may be explained by its enhanced signaling through the MAPK pathway 
and higher p53 degradation ability compared to prototype E6 (Pillai et al., 2002). 
Differences in the sequences of HPV 16 LCR affecting transcription factor 
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binding sites such as AP-1, Oct-1, TEF-1 and Y Y l have been found to alter the 
transforming activities and transcription activities of the E6 promoter (Kammer et al., 
2002, Park et al., 1999). 
1.5 Prevention by vaccination 
HPV are associated with diseases ranging from genital warts to invasive cancers. 
Vaccination is regarded as the primary prevention of infection. 
As HPV cannot be cultured, it is impossible to develop inactivated HPV vaccine. 
Rather, the current HPV vaccine is composed of the virus-like particles (VLPs). HPV 
virus-like particles are viral capsids that contain the major capsid protein, L I . When 
the L I proteins are expressed in eukaryotic cells, they self-assemble into virus-like 
particles, with the morphology similar to native virions. The VLP vaccines are highly 
immunogenic and show strong HPV type restriction. 
The first HPV vaccine, Gardasil® is now available on market, which was 
approved by Food and Drug Administration (FDA) in June 2006. Gardasil® is 
comprised of a mixture of L I virus-like particles of four HPV types (HPV 16 and 18, 
which caused more than 75% of cervical cancer worldwide, and HPV 6 and 11, 
which are responsible for common genital warts). Efficacy of the vaccine was 
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evaluated and it was shown that the vaccine prevented 98% of HPV 16/18 related 
high-grade cervical lesions over an average of three years (FUTURE II study group, 
2007). Another HPV vaccine targeting the HPV16 and 18 (CervarixTM) has 
completed the phase I I I trials, and was approved by the Therapeutic Goods 
Administration (TGA) of Australia in May 2007. 
Although the HPV vaccine showed high efficacy, vaccination should not replace 
the original screening programme. Since the present vaccine covers only HPV 16 and 
18, even i f the vaccine is 100% effective, it can only prevent about 75% of the 
cervical cancers (Schiller and Davies, 2004). 
1.6 Objectives 
The project is divided into two parts. In the first part, the HPV 
genotype-specific prevalence in the general women population in Hong Kong was 
accessed. 
Previous studies showed that HPV 16 was the most prevalent type found among 
invasive cervical cancer cases worldwide, followed by HPV 18, 45, 31, 33, 58 and 52. 
However, the ranking of HPV types showed some variations among different 
geographic regions, and the prevalence for HPV52 and 58 were much higher in Asia 
(Clifford et al., 2003). We aimed to understand the distribution of genotype-specific 
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prevalence in Hong Kong, which is important for the development of vaccines for 
the prevention of cervical cancer in the Hong Kong women population. Moreover, 
the epidemiological risk profile of HPV infection was determined, which provided 
more information for controlling HPV-related cervical diseases. 
For the second part, the sequence variations of HPV52 E6 and E7 oncogenes, 
L I and LCR were examined. A much higher prevalence of HPV52 was observed in 
the Hong Kong women population in compared to other regions around the world. 
Thus, the second part of the project is focused on HPV52. By sequencing HPV52 E6, 
E7, L I and LCR region, different HPV52 variants were identified, and their 
associations with the development of cervical cancers were assessed. 
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Chapter 2 
Materials and methods 
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2.1 HPV type and prevalence distribution 
2.1.1 Study population 
Cervical samples from Chinese women enrolling for a Pap smear at the Shatin 
Community Cervical Cancer Screening Centre at Prince of Wales Hospital were 
collected during May-October 1998, and a face-to-face interview was conducted 
with each individual to determine their epidemiological characteristics, including 
their education level, marital status, living standard, number of sex partners, number 
of pregnancies, age at sexual activity onset, alcohol consumption, smoking habit 
and their history of sexually transmitted disease. The specimen collection and 
conduction of questionnaire were performed by the Shatin Community Cervical 
Screening Clinic under the supervision of Professor Alexander Chang. 
A total of 2604 Chinese women with completed questionnaire and an adequate 
quality of cervical samples were included in this study. 
2.1.2 Specimen and epidemiological data collection 
Cervical exfoliated cells were collected using Cytobrush (Hadwood Products 
Company, USA), and were performed by Dr. Cheung T H of the Department of 
Obstetrics and Gynecology. After preparing a smear for routine cytological 
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examination, the brush was then immersed and agitated in 10 mL of 
phosphate-buffered saline (PBS). Cells were pelleted by centrifugation for 10 
minutes at 900 g and resuspended in 1 ml of PBS, and stored at -70 °C until further 
analysis. 
The cervical smears were assessed and classified according to the Bethesda 
system for the cytologic diagnosis by Dr. May Yu of the Department of Anatomical 
and Cellular Pathology. Under the Bethesda system 2001, abnormal smears were 
classified as either low-grade or high-grade squamous intraepithelial lesions. 
Low-grade lesions included cells with koilocytosis as well as mild dysplasia, 
high-grade lesions included cells with moderate to severe dysplasia and carcinoma 
in-situ. For smears containing atypical cells that could not be identified as LGSIL or 
HGSIL were classified as atypical squamous cells of uncertain significance 
(Solomon et al., 2002). 
2.1.3 DNA extraction 
DNA was extracted by BILATEST Genomic DNA Kit (BILATEC, 
Heidelbergerstr). Fifty microlitres of each cervical scrape sample was added to a well 
of a 96-well plate and mixed with 65 |LIL of lysis buffer and incubated for 1 min at 
room temperature. Eight microlitres of magnetic beads and 110 fxL of binding buffer 
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were added and pelleted using the magnetic separator. Pellet was washed and 
resuspended using 190 )LIL of washing buffer A, followed by 300 |LIL of washing 
buffer B. The extracted DNA was eluted with 50 [iL o f elution buffer. 
2.1.4 PGR amplification of DNA 
Two sets of PGR primers were used for DNA amplification. The BetaGPl/2 
primers (Table 2.1) target a 355-bp fragment of the housekeeping beta-globin gene 
(Lo et al., 1989). PGMY09/11 is a pool of primers (Table 2.2) targeting a 450-bp 
fragment of HPV L I region, which was introduced in 2000. PGMY09/11 can detect 
42 HPV genotypes (Gravitt et al., 2000,van Doom et al., 2002). Lysates from human 
leukocytes were used as positive control for Beta-GPl/Beta-GP2 PGR. Lysates from 
CaSki cells (HPV 16 positive) (ATCC no. CRL-1550, USA) and HeLa cells (HPV 18 
positive) (ATCC no. CCL-2, USA) were used as positive control for PGMY09/11 
PGR. Distilled water was used as negative control once every five samples to check 
for PCR contamination. 
2.1.4.1 PCR for Beta-globin 
To assess the quality of the DNA extracted from the samples, PCR for 
Beta-globin was performed in fifty samples, which were picked up randomly from 
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the 2604 samples. 
PCR was performed in a 50-|uL reaction mixture containing Tris-HCl, KCl, 
(NH4)2S04, 1.5 m M MgCb, 1 unit of HotStarT^^ DNA polymerase (QIAGEN, 
Germany), 200 |LIM of each dNTP (Amersham Biosciences, UK) and 0.25 |LIM of 
each BGPl /2 primer. Five microlitres of extracted DNA was used as template. The 
PCR cycling conditions included an initial denaturation and enzyme activation at 95 
for 15 min, followed by 40 cycles of 1 min denaturation at 94 1 min annealing 
at 58 °C and 1 min extension at 72 A final extension was carried out at 72 for 8 
min. 
2.1.4.2 PCR for HPV DNA 
PCR was performed in a 50-|iL reaction mixture containing Tris-HCl, KCl, 1.5 
m M MgCb, 1.5 units of HotStarr^^ DNA polymerase, 200 | iM of each dNTP, 0.25 
[ iM of each primer. Five microlitres of extracted DNA was used as template. The 
PCR cycling conditions included an initial denaturation and enzyme activation at 95 
for 15 min, followed by 40 cycles of 1 min denaturation at 94 ^C, 1 min annealing 
at 55 and 1 min extension at 72 A final extension was carried out at 72 °C for 8 
min. 
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Table 2.1. Primer sequences of Beta-globin PGR 
BGPl/2 PCR primer sequences 
Forward primer 5，-ATG GTG CAC CTG ACT CCT GAG G-3' 
Reverse primer 5，-GCC ATC ACT A A A GGC ACC GAC G-3 ‘ 
Table 2.2. Primer sequences of PGMY09/11 PCR 
PGMYQ9/11 PCR primer sequences 
Forward primer 
PGMYl 1-A 5 丨-GCA CAG GGA CAT AAC A A T GG-3’ 
P G M Y l l - B 5,-GCG CAG GGC CAC AAT A A T GG-3' 
PGMYl 1-C 5’-GCA CAG GGA CAT AAT AAT GG-3' 
PGMYl 1-D 5'-GCC CAG GGC CAC AAC AAT GG-3' 
PGMYl 1-E 5’-GCT VAG GGT TTA AAC AAT GG-3’ 
Reverse primer 
PGMY09-F 5'-CGT CCC A A A GGA AAC TGA TC-3' 
PGMY09-G 5'-CGA CCT AAA GGA AAC TGA TC-3' 
PGMY09-H 5’-CGT CCA AAA GGA AAC TGA TC-3丨 
PGMY09-I 5丨-GCC AAG GGG AA CTG ATC-3' 
PGMY09-J 5'-CGT CCC AAA GGA TAC TGA TC-3' 
PGMY09-K 5丨-CGT CCA AGG GGA TAC TGA TC-3' 
PGMY09-L 5,-CGA CCT AAA GGG AAT TGA TC-3丨 
PGMY09-M 5丨-CGA CCT AGT GGA AAT TGA TC-3' 
PGMY09-N 5’-CGA CCA AGG GGA TAT TGA TC-3' 
PGMY09-P 5丨-GCC CAA CGG AAA CTG ATC-3’ 
PGMY09-Q 5'-CGA CCC AAG GGA AAC TGG TC-3' 
PGMY09-R 5'-CGT CCT AAA GGA AAC TGG TC-3' 
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2.1.5 HPV typing by reverse line-blot hybridization 
HPV genotyping was carried out by reverse line-blot hybridization using the 
L INEAR ARRAY HPV Genotyping Kit (Roche Molecular Systems, Inc., USA). The 
primer mix contained biotinylated primers for the amplification of DNA fragment of 
approximately 450-bp from the L I gene of 37 HPV genotypes, and a 268-bp of 
human Beta-globin gene as specimen quality control. The amplicons were then 
denatured and hybridized with the HPV and Beta-globin oligonucleotide probe 
blotted as lines on the genotyping strips. Streptavidin-horseradish peroxidase 
conjugate was added to bind to the biotin-labelled amplicon hybridized on the strip, 
and visualized as blue lines after adding substrate solution. 
For the amplification, PGR was performed in a 100-|iL reaction mixture 
containing 50 |LIL of extracted DNA and 50 pL of HPV master mix MMX from the 
L INEAR ARRAY HPV Genotyping Kit (Roche Molecular Systems, Inc., USA), that 
containing Tris buffer, KCl, MgCb, Am^WTaq Gold DNA polymerase, dNTPs and 
biotinylated primers. The PGR cycling conditions included an initial denaturation 
and enzyme activation at 50 for 2 min then 95 for 9 min, followed by 40 cycles 
of 1 min denaturation at 95 1 min annealing at 55 and 1 min extension at 72 
A final extension was carried out at 72 °C for 5 min. 
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For the hybridization and detection reaction, 100 juL of denaturation solution 
was added to 100 juL of each PCR product. Seventy-five microlitres of the denatured 
amplicon was added to each well of the amplicor typing tray with 4 mL of preheated 
hybridization buffer (4X saline sodium phosphate EDTA [SSPE] and 0.5% SDS) and 
a hybridization strip coated with HPV specific probes. The tray was then incubated 
for 30 min at 53 °C and shaken at 60 rpm, and then washed with 4 mL of preheated 
stringent wash buffer ( I X SSPE and 0.1% SDS) for 15 min at 53 and 60 rpm. 
After washing, 4 mL of conjugate was added and incubated for 30 min at 60 rpm at 
room temperature. The tray was then washed twice with ambient wash buffer for 10 
min at 60 rpm at room temperature. Four millilitres of citrate buffer was added to 
each strip and shaken for 5 min at 60 rpm at room temperature. Four millilitres of 
SUB A and 1 ml of SUB B were added, and shaken for 5 min at 60 rpm at room 
temperature for colour development, and followed by rinsing with distilled water. 
Results were recorded within one day. Only samples with positive results for both 
Beta-globin probe lines were included. A negative control was included for each 
batch of samples tested. 
2.1.6 Statistical methods 
Al l statistical analyses were done using the SPSS software (version 15.0; SPSS 
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Inc., USA). The association between epidemiologic variables and the prevalence o f 
HPV was examined first by age-adjusted analyses with odds ratios, 95% confidence 
intervals, and P values calculated by logistic regression using the Enter method. 
Variables wi th P <0.08 by age-adjusted analyses were included in the multivariate 
analysis by multiple logistic regressions using the Enter method. 
The analyses on associations were initially performed for all HPV types 
combined, and then for HPV groups categorized by oncogenicity (Cogliano et al., 
2005, Munoz et al., 2003) and, different alpha-HPV species groups (de Villiers et al., 
2004)(Table 2.3). HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 
were categorized as high-risk types; HPV 6, 11, 40, 42, 43，44, 54, 61, 70, 72, 81, 
CP6108 and other uncharacterized HPV types were categorized as low-risk types in 
our study. 
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Table 2.3 Classification of HPV types in different alpha-papillomavirus species 
Alpha species HPV types 
Alpha-1 32, 42 
Alpha-2 3, 10, 28, 29, 78 
Alpha-3 61,62, 72,81, 83, 84, 86, 87, 89 
Alpha-4 2, 27, 57 
Alpha-5 26,51,69, 82 
Alpha-6 30, 53, 56, 66 
Alpha-7 18, 39, 45,59, 68, 70, 85 
Alpha-8 7, 40, 43,91 
Alpha-9 16,31,33,35, 52,58, 67 
Alpha-10 6, 11, 13,44,74 





- ,only animal papillomavirus, and no HPV is classified as alpha-12 species. 
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2.2 HPV 52 sequence variation 
2.2.1 Study population 
Eight subjects with HPV52 infection identified from first part o f the study, and 
124 subjects with HPV52 infection identified during the course of previous studies 
(Chan 2001, 2002c, 2002d, Tarn 2004) using the PGMY09/11 PGR and HPV typing 
by Roche L INEAR ARRAY HPV Genotyping Ki t (as described in 2.1) were 
included. These stored samples, including cervical scrape samples, 
paraffin-embedded tumour tissues and fresh frozen tumour tissues, were used for the 
current study for sequencing of HPV52 E6, E7, L I open reading frames and LCR. 
A total of 45 overseas samples (ten from Taiwan, 21 from Korea, eight from UK, 
four from Italy, one from Argentina and one from Canada) that were known to have 
HPV52 were contributed by overseas collaborators. 
2.2.2 Specimen processing 
Cervical exfoliated cells were collected and stored as mentioned in 2.1.2. 
Fresh biopsies were collected in viral transporting medium taken at the time of 
operation. The biopsies were stored at -70 until further analysis. 
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For each paraffin-embedded cervical carcinoma tissue block, four to five slides 
of 5-|Lim thick tissue section were cut and transferred into 1.5-mL microfuge tubes. 
Sections adjacent to the beginnings and endings of cutting were examined to ensure 
the inclusion of tumor tissue. Knife was decontaminated using alcohol after cutting 
of each specimen to avoid cross-contamination between specimen blocks. 
Cervical smears were assessed and classified according to the Bethesda system 
as described in 2.1.2. Histological diagnosis on biopsies was performed according to 
the WHO classification (IARC Press, 2001). 
2.2.3 DNA extraction 
DNA was extracted using a commercially available kit, the QIAamp DNA Mini 
Kit (QIAHEN, Germany.) The paraffin-embedded tissues were first deparaffinized 
twice with 1200 \iL of xylene. The pellets were washed three times with 1200 |LIL of 
100% ethanol to remove residual xylene. Following the manufacturer's protocol, 180 
|LIL of Buffer ATL and 20 ^iL of proteinase K were added to the tissue, and digested 
overnight at 56^C. After digestion, 200 |xL of Buffer A L was added and incubated for 
10 min at 70 followed by mixing with 200 |LIL of 100% ethanol. The mixture was 
transferred to the spin column and centrifuged for 1 min. The column was washed 
with 500 )iL of Buffer A W l and centrifuged at 6200 g for 1 min, followed by 500 ^L 
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of Buffer AW2 and centrifuged at 162000 g for 3 min. The DNA was eluted with 200 
\iL o f Buffer A E at room temperature, and centrifuged at 6200 g for 1 min. 
2.2.4 PCR amplification for sequencing 
Specific primers for amplifying HPV52 E6 and E7, L I gene and LCR were 
designed based on the HPV52 prototype sequence (GenBank accession number: 
X74481) using the primer express software version 2.0 (Applied Biosystems, USA). 
The designed primers were checked for specificity using BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST/). (Table 2.4) 
2.2.4.1 Optimization of gene-specific PCR 
Each PCR for HPV52 E6, E7, L I open reading frames and LCR for sequencing 
was optimized by trying different annealing temperatures at 56 58 and 60 
by using serial dilutions of HPV52 positive samples. After optimizing the annealing 
temperature, primer concentrations ranging from 0.125, 0.25 and 0.5 }xM were 
compared to determine the optimal primer concentration. Each PCR was performed 
in a 50-)aL reaction mixture containing Tris-HCl, KCl, 1.5 m M MgCb, 1.25 units of 
HotStarra^ DNA polymerase, 200 | iM of each dNTP. The PCR cycling conditions 
included an initial denaturation and enzyme activation at 95 for 15 min, followed 
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by 40 cycles of 1 min denaturation at 94 1 min annealing, and 1 min extension at 
72 A final extension was carried out at 72 °C for 8 min. 
2.2.4.2 Validation of type-specificity of gene-specific PCRs 
Each PCR for HPV52 E6, E7, L I open reading frames and LCR for sequencing 
was validated for type-specificity by using HPV 16, 18, 33, 45, 52, 58 positive 
samples as template. Each PCR reaction was performed using the optimized 
annealing temperature and primer concentration. PCR products were analyzed on 2% 
agarose gel by electrophoresis with ethidium bromide staining to make sure the 
primers were specific for HPVS2 only and demonstrated no cross-reactivity. 
2.2.4.3 PCR for HPV52 E6 and E7 
HPV52 E6 and E7 gene was amplified using the HPV52 E6/7-F and HPV52 
E6/7-R primers, the amplicon size was 1246 bp. PCR was performed in a 50卞L 
reaction mixture containing Tris-HCl, KCl, 1.5 mM MgCb, 1.25 units of HotStarJ^/^ 
DNA polymerase (QIAGEN, Germany), 200 ^iM of each dNTP (Amersham 
Biosciences, UK), 0.25 | iM of each primer. Five microlitres of extracted DNA was 
used as template. The PCR cycling conditions included an initial denaturation and 
enzyme activation at 95 for 15 min, followed by 40 cycles of 1 min denaturation 
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at 95 1 min annealing at 58 and 1.5 min extension at 72 ''C. A final extension 
was carried out at 72 for 8 min. 
For weak amplicons, a nested PGR using HPV52-E6/7-out l-M13 and 
HPV52-E6/7-out2 primers with amplicon size o f 900 bp was added. PCR was 
performed in a 50-^L reaction mixture containing Tris-HCl, KCl, 1.5 m M MgCb, 
1.25 units o f HotStarTa^ D N A polymerase, 200 iiiM o f each dNTP and 0.125 |LIM o f 
each primer. One microlitre of the amplified E6/7 amplicon in 1:10 dilution was used 
as template. The PCR cycling conditions were the same as the first-round PCR. 
2.2.4.4 PCR for LI gene 
HPV52 L I gene was amplified using two PCR reactions. HPV52-L l -out l and 
HPV52-L1A-R primers amplified the first fragment of the L I gene (L I A) o f 1210 bp 
in size. PCR was performed in a 50-|LtL reaction mixture containing Tris-HCl, KCl, 
1.5 m M MgCb, 1.25 units of HotStarT^g DNA polymerase, 200 | iM o f each dNTP 
and 0.5 |LIM o f each primer. Five microlitres o f extracted DNA was used as template. 
The PCR cycling conditions included an initial denaturation and enzyme activation at 
95 for 15 min, followed by 40 cycles of 1 min denaturation at 95 1 min 
annealing at 56 and 1.5 min extension at 72 A final extension was carried out 
at 72 for 8 min. 
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For weak amplicons, a nested PCR using the same set of primers were 
performed in a 70-|iL reaction mixture containing Tris-HCl, KCl, 1.5 mM MgCb, 
1.75 units o f HotStarJa^ DNA polymerase, 200 | iM of each dNTP and 0.25 of 
each primer. One microlitre of the amplified L I A amplicon in 1:10 dilution was used 
as template. The PCR cycling conditions were the same as the first-round PCR. 
HPV52-L1B-F2 and HPV52-Ll-out2 primers amplified the second fragment of 
the LI gene (L IB) of 912 bp in size. PCR was performed in a 50-|LIL reaction mixture 
containing Tris-HCl, KCl, 1.5 m M MgCb, 1.25 units of HotStarTag DNA 
polymerase, 200 juM of each dNTP and 0.5 jxM of each primer. Five microlitres of 
extracted DNA was used as template. The PCR cycling conditions were the same as 
the PCR for L I A. 
For weak amplicons, the original samples were re-amplified using two units of 
HotStarTa^ DNA polymerase. 
2.2.4.5 PCR for long control region (LCR) 
The long control region (LCR) of HPV52 was amplified using the 
HPV52-LCR-F1 and HPV52-LCR-R primers, the amplicon size was 1120 bp. PCR 
was performed in a 50-|LIL reaction mixture containing Tris-HCl, KCl, 1.5 m M MgCb, 
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1.25 units o f HotStarT^^ DNA polymerase, 200 |xM o f each dNTP and 0.25 | iM of 
each primer. Five microlitres of extracted DNA were used as template. The PCR 
cycling conditions included an initial denaturation and enzyme activation at 95 for 
15 min, followed by 40 cycles of 1 min denaturation at 95 1 min annealing at 58 
and 1.5 min extension at 72 A final extension was carried out at 72 for 8 
min. 
For weak amplicons, the original samples were re-amplified using two units of 
HotStarTag DNA polymerase. 
2.2.5 Purification of PCR products 
PCR products were purified by MicroSpin™ S-400 HR Columns (Amersham 
Pharmacia, USA) to remove primer dimers. The resin in the column was resuspended 
by vortexing and spinned at 900 g for 1 min. PCR products were added to each of the 
column and centrifuged for another 2 min, the purified products were collected into 
1.5 ml microfuge tubes. 
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2.2.6 Sequencing 
2.2.6.1 Preparation of template 
Sequencing reaction was performed using the A B I Prism BigDyeTM 
Terminator v. 3.1 Cycle Sequencing kit (Perkin-Elmer Cetus, USA). The sequencing 
reaction was performed in a 20-|aL mixture containing 2 |iL o f BDT ready reaction 
mix, 3 |LIL BigDye sequencing buffer, 3.2 pmol of primer and 10 |iL o f template DNA. 
Reaction included an initial denaturation at 96 for 1 min, followed by 25 cycles of 
10 sec denaturation at 96 5 sec annealing at 50 and 4 min extension at 60 ""C. 
The primers HPV52-E6/7-outl-M13 and HPV52-E6/7-out2 were used for 
sequencing of the E6 and E7 genes, HPV52-L l -out l , HPV52-L1A-R, 
HPV52-L1AM, HPV52-L1B-F2 and HPV52-Ll-out2 for L I , HPV52-LCR-F3 and 
HPV52-LCR-R were for sequencing of the long control region (Table 2.4). 
2.2.6.2 Purification of template 
Sequencing reaction products were purified by DyeEx 2.0 Spin kit (QIAGEN, 
Germany). The resin in the spin column was resuspended by vortexing and spinned 
at 900 g for 3 min. PGR products were added to each of the column and centrifuged 
for another 3 min, the purified products were collected into 1.5 mL microflige tubes. 
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2.2.6.3 Sequencer and data analysis 
Two microlitres of purified sequencing product were resuspended in 10 juL of 
Hi-Di formamide (Applied Biosystems, USA) and heated for 2 min at 95 and 
then chilled on ice. The sample was injected into the A B I Prism 3030 Genetic 
Analyzer for sequencing. A B I PRISM Seqscape software v. 2.5 was used for 
sequence variation analysis of HPV E6, E7, L I gene and LCR. The sequences were 
compared with the HPV52 prototype available in the GenBank (Accession No. 
X74481). Samples were sequenced in both forward and reverse direction to confirm 
any variation detected. 
Putative transcription factor binding sites on the LCR were revealed using 
TFSEARCH software (http://molsunl.cbrc.aist.go.jp/research/db/ TFSEARCH.html), 
which searches for highly correlated sequence fragments against the TFMATRIX 
transcription factor binding site profile database. The putative transcription factor 
binding sites which are in forward direction, having a human origin and with score 
over 85.0 was regarded as significant. 
2.2.7 Statistical methods 
The oncogenic risk association between variants and cervical cancer 
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development were assessed by calculating the odds ratios. Odds ratio less than one 
was regarded as having a negative association; odds ratio more than one was 
regarded as having a positive association. A 95% confidence interval that did not 
include the value one was regarded as significant. The odds ratios of invasive 
cervical cancer versus normal, and the odds ratios of CIN I I I and invasive cervical 
cancer versus normal of different variants were calculated. Chi-Squared test or 
Fisher's exact test, when one or more expected cell values were less than 5, were 
performed to evaluate for the significant of association. Two-tailed 尸-values less than 
0.05 were considered as statistically significant. The statistical analyses were 
performed using the Epi Info software (version 6.0; USC Inc., USA). 
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Table 2.4 Primer sequences for HPV52 sequencing 
HPV52 PCR primer sequences 
HPV52-E6/7-F 5’-GCA CTA CAC GAC CGG TTA CG-3’ 
HPV52-E6/7-R 5'-TTG CAC GCG GAC TAC CAT GT-3' 
5'-TGT A A A ACG ACG GCC AGT TAG GGT GTA 
HPV52-E6/7-outl-M13 
ACC GAA AAC GG -3’ 
HPV52-E6/7-out2 5'- GCC TCT ACT TCA AAC CAG CC-3' 
HPV52-Ll-out l 5’-ATG TCC ATT GAG TCA GGT CC-3’ 
HPV52-L1A-R 5'-ACG AGT GGT ATC CAC AAC TG-3' 
HPV52-L1AM 5,-TGT CTG GCC TGC AAT ACA-3' 
HPV52-L1B-F2 5’-GCA ATA CTG CCA CTG TGC AA-3' 
HPV52-L1 -out2 5'-TTA CTC ATG TGG GTG CAA CC-3' 
HPV52-LCR-F1 5'-CCA CCA CCG TCT GCA TCT T-3' 
HPV52-LCR-R 5'-CCT CAC ACA ATT CGT GCA GG-3’ 





3.1 HPV type and prevalence distribution 
3.1.1 Study population 
A total o f 2604 Hong Kong Chinese women were recruited. Their mean age was 
43.3 years (range = 19-83 years, SD = 9.3 years), 63% women were within the age of 
36-50 years (Figure 3.1). Ninety-eight point seven percent o f women had a normal 
cervix, 0.4% had cervical intraepithelial neoplasia I I or above (Table 3.1). One third 
of the participants were having their first Pap smear. 
Nearly 94% of the individuals were living in Hong Kong for more than 10 years. 
Sixty-two percent of the women had an education level of secondary school or above. 
Most of the individuals (97%) were married and with one or more children. Only a 
small percentage (3.8%) of the individuals was smoker. However, nearly 40% of 
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Figure 3.1 Age distribution of 2604 Hong Kong Chinese women attending 
cervical cancer screening 
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Table 3.1 Distribution of cervical cytology results of 2604 Hong Kong Chinese 
women 
Cervical cytology No. % 
Normal 2326 89.3 
Infection 133 5.1 
ASCUS 52 2.0 
Reactive 38 1.5 
Atypical 16 0.6 
HPV(by cytology) 5 0.2 
CIN I 24 0.9 
CIN I I 3 0.1 
CIN I I I 5 0.2 
Invasive cervical cancer 2 0.1 
ASCUS, atypical squamous cells of undetermined significance; HPV, human Papillomavirus; CIN, 
cervical intraepithelial neoplasia grade I to III. 
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Table3.2 Distribution of epidemiological variables among 2604 Hong Kong 
Chinese women 
Variable No. % 
Years in Hong Kong 
<10 161 6.2 
11-20 392 15.1 
>21 2051 78.8 
Education 
Primary or below 991 38.1 
Secondary 1461 56.1 
Tertiary or above 151 5.8 
Marital statue 
Single 97 3.7 
Cohabit 6 0.2 
Married 2276 87.4 
Separated 103 4.0 
Widow 121 4.6 
Age at first sexual intercouse 
<17 173 6.6 
>18 2423 93.0 
Lifetime no. of sex partners 
<1 2199 84.4 
2-3 341 13.1 
4-18 64 2.5 
Previous Pap smear 
Never 820 31.5 
Ever 1782 68.4 
No. of full-term pregnancies 
0 183 7.0 
1-3 1470 56.5 
4-13 951 36.5 
Menopause 
No 2103 80.8 
Yes 501 19.2 
Treatment for cervical lesion 
Never 2359 90.6 
Ever 245 9.4 
History of STD 
Never 2556 98.2 
Ever 45 1.7 
Contraceptive used 
None 481 18.5 
Injection 31 1.2 
Condom 698 26.8 
Pill 82 3.1 
lUCD 122 4.7 
Tubal ligation 675 25.9 
Others 14 0.5 
Smoker 
No 2505 96.2 
Yes 99 3.8 
Smoker in family 
No 1438 55.2 
Yes (husband) 987 (882) 37.9 (33.9) 
Not known 179 6.9 
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3.1.2 HPV prevalence 
3.1.2.1 Prevalence for HPV infection 
HPV DNA was detected in 175 samples (6.7%) (Figure 3.2), of which 130 
samples (5.0%) were infected with high-risk HPV types. The blue bars in Figure 3.3 
show the prevalence of HPV infection of the five most common alpha species. The 
alpha-9 species which contains most of the high-risk HPV types (HPV 16, 31, 33, 35, 
52, 58, 67) shown the highest prevalence (3.8%). The prevalence of vaccine 
preventable HPV 16 and 18 was 1.7%. The prevalence of HPV52, 58, which were 
more commonly found in Asia, including Hong Kong, was 1.2%. 
Multiple infections were found in 41% of all the HPV positive samples, most of 
these samples (24%) harboured two HPV types. However, a small proportion (5%) 
harboured more than five HPV types (Figure 3.4). 
Figure 3.5 shows the distribution of HPV genotypes among 175 HPV-positive 
women, HPV 16, 52 and 58 were the first three most common HPV types in Hong 
Kong. 
Table 3.4 shows the HPV prevalence according to cytology results. Only 4.3% 
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Figure 3.2 Agarose gel electrophoresis result of HPV PCR using PGMY09/11 
primers 
?h\\74-HaeIII was used as molecular marker. The expected product size is 450 bp. Lane 1-4 show 
samples without HPV DNA, and was regarded as negative. Lane 5 is a sample with HPV DNA, and 
was regarded as positive. 
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Figure 3.3 Prevalence for any, high-risk, low-risk HPV, HPV of different alpha 
species, HPVl6/18/52/58 infection in 2604 Hong Kong women 
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Figure 3.5 HPV genotypes distribution among 175 HPV-positive women 
Other HPVs include HPV6, 26, 35, 42, 45, 67, 69, 73, IS39 and CP6 108. 
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Table 3.3 Distribution of HPV genotypes among 175 HPV-positive women. 
No. of HPV ——u.“ .丨 Positive for HPV types 丨 一 N o . of 
infection High-risk types Low-nsk types 
16 18 31 33 51 52 56 58 59 Other' 11 40 61 62 71 81 O t h e r � ^ 
i - + 2 6 (14.9) 
1 + 4 (2.3) 
1 + 13 (7.4) 
1 - + 5 (2.9) 
1 - - + 2 (1.1) 
1 - - - + 2 (1.1) 
1 - - - - + 4 (2.3) 
1 + 21 (12) 
1 + 1 (0.6) 
1 + 12 (6.9) 
1 + 4 (2.3) 
1 - - - + - - - - 2 (1.1) 
1 + - - - 2 (1.1) 
1 + 2 (1.1) 
1 + - - 1 (0.6) 
1 + - 4 (2.3) 
2 — — — — • — - + — — — — + — 1 (0.6) 
2 — — — — — — — — + — + — — — — - I (0.6) 
2 + + 2 (1.1) 
2 + + 2 (1.1) 
2 + - - + 1 (0.6) 
2 + - - - + 1 (0.6) 
2 + - - - - + 1 (0.6) 
2 + + 2 (1.1) 
2 + + 1 (0.6) 
2 + + - - 1 (0.6) 
2 + + 2 (1.1) 
2 + + - 1 (0.6) 
2 - + + 1 (0.6) 
2 - + + - 1 (0.6) 
2 + _ _ _ _ + . - - 1 (0.6) 
2 - - - + + 1 (0.6) 
2 - - - + + - - - - 2 (1.1) 
2 _ _ _ + - + - 1 (0.6) 
2 + + 3 (1.7) 
2 + - + 1 (0.6) 
2 - - - - + + - - - - - 2 (1.1) 
2 - - - - + - - + 1 (0.6) 
2 - - - - + + - 1 (0.6) 
2 - - - - + + 1 (0.6) 
2 + - + 2 (1.1) 
2 + + 2 (1.1) 
2 + + 1 (0.6) 
2 + + 2 (1.1) 
2 + - - - + 1 (0.6) 
2 + - - + - 1 (0.6) 
2 - - - + + - - 1 (0.6) 
3 + + + 1 (0.6) 
3 + + - - - - + 1 (0.6) 
3 + + + 1 (0.6) 
3 + + - - + 1 (0.6) 
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No. of HPV Positive for HPV types ‘ ^ ^ ^^ 
infection High-risk types Low-risk types on (%) 
16 18 31 33 51 52 56 58 59 Other^ 11 40 61 62 71 81 Other] ^ 
3 - + + - - - - + 1 (0.6) 
3 - + + + 1 (0.6) 
3 - + + + 1 (0.6) 
3 - - + - + - - + 1 (0.6) 
3 - - + - + + 1 (0.6) 
3 - - - + - + + - - - 1 (0.6) 
3 + - - - + - - + - - - - 1 (0.6) 
3 + - - + - - - + - 1 (0.6) 
3 - - - - + - - + + 1 (0.6) 
3 + + - - + 1 (0.6) 
3 + + + 1 (0.6) 
3 + - - - - + + - - 1 (0.6) 
3 + - - - - + - - + 1 (0.6) 
4 + - - - + + + 1 (0.6) 
4 - - + - - - - + - - + - - - - - + 1 (0.6) 
4 + - + - - - - - + - - - - - - - + 1 (0.6) 
4 + - + - - - + + - - 1 (0.6) 
4 + + + - - - + 1 (0.6) 
4 - + - - + + - - + 1 (0.6) 
5 + - - + - - - + - + + 1 (0.6) 
5 - + - + + + + - - 1 (0.6) 
5 - - + + - - - + - - - + - - � + - 1 (0.6) 
5 + - - + - + - - - + + 1 (0.6) 
6 - + + + - + - - - + + 1 (0.6) 
二 i v e 32 16 7 u 14 32 6 31 11 10 6 12 10 6 16 175 
for HPV 
1 + indicates presence of the HPV type; - indicates absence of the HPV type 
2 Other high-risk HPVs include HPV35, 39, 45 and 55. 





























































































































































































































































































































































































































































































3.1.2.2 HPV age-specific prevalence 
The prevalence for HPV infection peaked (14.0%) at the 26-30 years old 
age-group and gradually declined to 5.6% in the 41-45 age-group. A minor peak was 
observed for elder women (46-55 years old). The patterns o f HPV prevalence were 
similar in high-risk and low-risk HPVs, the HPV infection peaked at young age (<30 
years) and declined gradually and a second peak was observed in 46-55 age-groups. 
Vaccine preventable HPV 16 and 18 also showed a peak in the 26-30 age-group. 
However, the prevalence declined as age increased without an obvious second peak 
in elder age (Figure 3.6). 
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Figure 3.6 Age-specific prevalence of HPV infection in 2604 Hong Kong women 
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Alpha-3, -5, -6, -7 and -9 species were the most common HPV species found in 
Hong Kong Chinese women, and the age-specific prevalence showed two 
distinguished patterns. For alpha-3 and -6 species, they showed two major peaks of 
infection at young age and elder age of similar level of prevalence. The alpha-5, -7 
and -9 species showed a major peak at young age (26-30) and declined with age, a 
minor rise in prevalence in older age (46-55 years) was observed (Figure 3.7). 
Figure 3.8 shows the pattern of age-specific prevalence of the six most common 
HPV genotypes. The prevalence of HPV 16, 18 and 51 infections respectively peaked 
at young age and decreased with increase in age. A different pattern was observed for 
HPV33, 52 and 58 that showed two peaks of infection, a major peak in the 26-35 
age-group, and a minor peak in the 46-55 age-group. 
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(A) Age-specific prevalence of the alpha-3 and -6 species that showed two major peaks of infection. 
(B) Age-specific prevalence of the alpha-5, -7 and -9 species that had a major peak at young age and a 
minor peak in older women. 
Alpha-3 species includes HPV61, 62, 72, 81, 83, 84, CP6108; alpha-5 species includes HPV26, 51, 69, 
82, IS39; alpha-6 species includes HPV53, 56, 66; alpha-7 species includes HPV18, 39, 45, 59, 68, 70; 
alpha-9 species includes HPV16, 31, 33, 35, 52’ 58, 67 (High-risk HPV types are bold). 
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Figure 3.8 Age-specific prevalence of the six most common HPV types 
(A) Age-specific prevalence of HPV 16, 18 and 51 that peaked at young age and decreased with 
increase in age. (B) Age-specific prevalence of HPV33, 52 and 58 that showed two peaks of infection. 
72 
3.1.3 Epidemiological risk profile 
3.1.3.1 Age-adjusted analyses 
After adjusted for age, HPV infection of any types was associated with previous 
treatment for cervical lesions, number of lifetime sex partners, use of barrier 
contraception and oral contraception, and smoking behavior o f the participants and 
their family members (Table 3.5). When focused on separate oncogenic HPV 
infection risk group and different HPV alpha species, different risk profiles were 
observed (Table 3.6). The smoking behavior of participants and their family 
members were associated with high-risk, low-risk HPV and alpha-5, -7, -9 HPV 
species, but not with alpha-3, -6 HPV species. The use of oral contraception was only 
associated with high-risk HPV and the age at first sexual intercourse was only 
associated with low-risk HPV. 
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Table 3 .5 A g e - a d j u s t e d preva lence o d d s rat ios ( O R s ) f o r any, h igh-r isk and low-r isk 
h u m a n p a p i l l o m a v i r u s ( H P V ) infect ions , accord ing to ep idemio log ica l variables . 
Any-type HPV High-risk HPV Low-risk HPV 
V 咖 bleCN) prevg^nce’ or(95%cI) P Prev^^nce，oR(95%CI) /> Prev=)^nce，0R(95%a) P 
Education 0.210 0.160 0.962 
Secondary or below (2346) 6.6 1.0 4.9 1.0 3.5 1.0 
Tertiary or above (257) 7.8 1.38 (0.83-2.28) 6.2 1.49(0.85-2.61) 3.1 0.98 (0.46-2.10) 
Previous Pap smear 0.402 0.483 0.517 
Never (820) 6.3 1.0 4.8 1.0 3.3 1.0 
Ever (1782) 6.9 1.16(0.82-1.63) 5.1 0.87 (0.59-1.29) 3.5 1.19(0.73-1.87) 
Treatment for cervical lesion a 0.002 0.000 0.512 
Never (2359) 6.3 1.0 4.5 1.0 3.6 1.0 
Ever (245) 11.0 2.04 (1.31-3.16) 9.8 2.55 (1.59-4.09) 2.4 0.754 (0.33-1.75) 
Marital statue 0.942 0.881 0.422 
Single (97) 11.3 1.0 9.3 1.0 8.2 
Married (2276) 6.6 0.88 (0.44-1.78) 4.9 0.83 (0.39-1.79) 3.4 0.62(0.27-1.43) 
Others (231) 5.6 0.89 (0.36-2.20) 3.9 0.79(0.28-2.19) 2.2 0.46(0.13-1.56) 
No. of full-term pregnancies 0.084 0.051 0.381 
0 (183) 6.0 1.0 3.8 1.0 3.8 1.0 
>1 (2421) 6.8 1.80 (0.92-3.49) 5.1 2.55 (1.00-5.06) 3.4 1.45 (0.63-3.34) 
Menopause 0.739 0.433 0.606 
No (2103) 7.1 1.0 5.3 1.0 3.6 1.0 
Yes (501) 5.0 1.11 (0.61-2.02) 3.8 1.32(0.66-2.66) 2.8 1.23 (0.56-2.70) 
Age at first sexual intercourse 0.067 0.068 0.024 
>18 (2423) 6.4 1.0 4.7 1.0 3.2 1.0 
<17(173) 11.6 1.61 (0.97-2.69) 9.2 1.70 (0.96-2.99) 7.5 2.08(1.10-3.92) 
Lifetime no. of sex partners 0.001 0.055 0.000 
<1 (2199) 5.8 1.0 4.4 1.0 2.8 1.0 
2-3 (341) 10.3 1.62 (1.08-2.43) 7.3 1.44 (0.90-2.31) 5.6 1.85(1.07-3.20) 
>4 (64) 18.8 2.97 (1.52-5.84) 12.5 2.34 (1.06-5.17) 15.6 5.26 (2.47-11.19) 
Histoiy ofSTD 0.635 0.681 0.282 
Never (2556) 6.7 1.0 5.0 1.0 3.4 1.0 
Ever (45) 8.9 1.29 (0.45-3.66) 6.7 1.28(0.39-4.22) 6.7 1.93 (0.58-6.39) 
Regular barrier contraception 0.034 0.145 0.79 
Yes (698) 5.9 1.0 4.7 1.0 2.9 1.0 
No (1906) 7.0 1.51 (1.03-2.21) 5.1 1.37(0.90-2.10) 3.7 1.61 (0.95-2.73) 
Oral contraception 0.041 0.034 0.705 
No (2522) 6.5 1.0 4.8 1.0 3.4 1.0 
Yes (82) 14.6 1.97(1.03-3.77) 12.2 2.15 (1.06-4.35) 3.7 0.79 (0.24-2.61) 
Smoker 0.000 0.000 0.005 
No (99) 6.2 1.0 4.5 1.0 3.2 1.0 
Yes (2505) 19.2 3.01 (1.74-5.19) 17.2 3.62 (2.03-6.46) 10.1 2.79 (1.36-5.74) 
Smoker in family b 0.000 0.000 0.004 
No (1438) 5.4 1.0 3.7 1.0 2.7 1.0 
Yes (987) 9.2 1.77 (1.29-2.42) 7.4 2.09(1.45-3.00) 5 1.87(1.22-2.88) 
First category serves as the reference for odds ratio (OR) calculation by logistic regression. CI, 
confidence interval; STD, sexually transmitted disease. Variables with P < 0.08 are shown in blue, 
a Local surgery including cauterization, cryotherapy, laser ablation or loop electrosurgical excision 
procedure. 
b 179 of the study population replied that they did not know whether there are smoker in family and 
was excluded from the analysis. 
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Table 3.6 Age-adjusted prevalence odds ratios (ORs) for alpha-5, -7，-9 and 
alpha-3, -6 human papillomavirus (HPV) infections, according to 
epidemiological variables. 
Alpha-5 ,-7，-9 HPV Alpha-3, -6 HPV 
VanableCN) prev^ n^ce, QR (950/0 CI) P Prev^ n^ce’ QR (950/0 CI) P 
Education 0.157 0.340 
Secondary or below (2346) 5.2 1.0 2.5 1.0 
Tertiaiy or above (257) 6.6 1.48 (0.86-2.55) 1.2 0.56 (0.17-1.83) 
Previous Pap smear 0.436 0.291 
Never (820) 5 1.0 2.6 1.0 
Ever (1782) 5.4 1.17(0.79-1.71) 2 0.73 (0.41-1.31) 
Treatment for cervical lesion ® 0.001 0.222 
Never (2359) 4.9 1.0 2.3 1.0 
Ever (245) 9.4 2.22 (1.38-3.56) 3.3 1.61 (0.75-3.44) 
Marital statue 0.675 0.525 
Single (97) 10.3 1.0 2.1 1.0 
Married (2276) 5.2 0.75 (0.36-1.57) 2.4 1.87 (0.42-8.25) 
Others (231) 3.9 0.65 (0.24-1.76) 2.6 2.61 (0.48-14.22) 
No. of full-term pregnancies 0.146 0.085 
0(183) 4.9 1.0 1.1 1.0 
>1 (2421) 5.3 1.72 (0.83-3.58) 2.5 3.60 (0.84-15.43) 
Menopause 0.690 0.243 
No (2103) 5.6 1.0 2.4 1.0 
Yes (501) 4 0.87 (0.44-1.72) 2.2 1.64 (0.71-3.77) 
Age at first sexual intercourse 0.101 0.101 
>18 (2423) 5 1.0 2.2 1.0 
<17 (173) 9.2 1.60 (0.91-2.82) 4.6 1.94 (0.88-4.27) 
Lifetime no. of sex partners 0.024 0.036 
<1 (2199) 4.7 1.0 2 1.0 
2-3 (341) 7.6 1.44 (0.91-2.29) 3.5 1.61 (0.82-3.15) 
>4 (64) 14.1 2.60(1.22-5.53) 7.8 3.42 (1.26-9.27) 
History of STD 0.336 0.704 
Never (2556) 5.2 1.0 2.4 1.0 
Ever (45) 8.9 1.67 (0.59-4.76) 2.2 1.13 (0.15-8.38) 
Regular barrier contraception 0.047 0.363 
Yes (698) 4.6 1.0 2.1 1.0 
No (1906) 5.6 1.54 (1.01-2.36) 2.5 1.33 (0.72-2.47) 
Oral contraception 0.118 0.670 
No (2522) 5.1 1.0 2.3 1.0 
Yes (82) 11 1.79 (0.86-3.73) 3.7 1.30 (0.39-4.33) 
Smoker 0.000 0.428 
No (99) 4.8 1.0 2.3 1.0 
Yes (2505) 18.2 3.73 (2.12-6.557) 4 1.54 (0.53-4.46) 
Smoker m family b 0.000 0.360 
No (1438) 3.8 1.0 2.2 1.0 
Yes (987) 8.2 2.29 (1.61-3.27) 2.7 1.28(0.76-2.15) 
First category serves as the reference for odds ratios (OR) calculation by logistic regression. CI, 
confidence interval; STD, sexually transmitted disease. Variables with P < 0.08 are shown in blue, 
a Local surgery including cauterization, cryotherapy, laser ablation or loop electrosurgical excision 
procedure. 
179 of the study population replied that they did not know whether there are smoker in family and 
was excluded from the analysis. 
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3.1.3.2 Multivariate analyses 
A l l variables with an age-adjusted P < 0.08 for HPV types in combined, 
high-risk, low-risk, alpha-5, -7, -9 and alpha-3, -6 species groups were subjected to 
multivariate analyses to assess the independent risk associations. Young age was 
associated with all groups except for the low-risk HPV group. Smoking behavior was 
the common variable with an independent risk association with HPV infections, of 
which, passive smoking (having a family member who smoked) was associated with 
infections with all HPV groups; and smoking was also associated with infections 
with all HPV groups except for the low-risk HPV group. Number of lifetime sex 
partners was associated only with low-risk and alpha-3, -6 HPV infections. However, 
the prevalence of HPV infection of all groups showed a trend of increasing HPV 
prevalence with the number of lifetime sex partners (Figure3.9). Number of full-term 
pregnancies, age at first sexual intercourse, use of barrier contraception and oral 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































18 ！ n 
16 i :. — = 1 
1 4 I — " " " j • Any-type HPV 
I j 
^ 1 2 I ^ I B High-risk HPV 
^ ' i • Low-risk HPV 
召 10 — ^ 
2 “ ： I • Alpha-5, -7, -9 HPV 
o “ 3 I 
o ' m m “ i B Alpha-3, -6 HPV 
.ti r - a - ‘ I 
差 6 I f l ™ q m 
4 h s b H H 。； _ ： ； mr 
；一 • • 
2 I : : 卜 : 二 
Q I ^ __mm„__L_J_LJ____H__I I LJ____WM 
<2 2-3 >3 
Lifetime no. o f sex partners 
Figure3.9 Prevalence for any-type, high-risk, low-risk HPV, alpha-5, -7，-9 HPV 
and alpha -3, -6 HPV infections according to number of lifetime sex partners 
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3.2 HPV52 sequence variation 
3.2.1 Study population 
A total o f 132 Hong Kong Chinese women tested positive for HPV52 DNA 
were recruited for HPV52 sequencing. Their mean age was 45.5 years (range = 23-88 
years, SD = 14.1 years). Twenty-eight (21.2%) women had a normal cervix, 20 
(15.2%) had CIN I / LGSIL, 31 (23.5%) had CIN I I / HGSIL, 33 (25.0%) had CIN 
I I I and 20(15.2%) had ICC. 
A total of 45 overseas women tested positive for HPV52 DNA were also 
recruited for HPV52 sequencing. Their mean age was 39.5 years (range = 20-73 
years, SD = 14.5 years). Eight (17.8%) women had a normal cervix, nine (20.0%) 
had CIN I / LGSIL, six (13.3%) had CIN I I / HGSIL, two (4.4%) had CIN III, and 
eight (17.8%) had ICC. Twelve women were of unknown pathology status. 
3.2.2 Sequence variability of HPV52 
The sequences were compared with HPV52 prototype (GenBank accession 
number: X74481). Isolates with complete nucleotide sequence homology to the 
prototype over the E6, E7 and L I regions were regarded as prototype-like variants. 
Among the 132 Hong Kong isolates, only 6.8% of prototype-like variants were found 
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(Table 3.8). No prototype-like variant was found from the Taiwanese, Korean and 
Argentinian isolates. However, prototype-like variants were found more frequently in 
the isolates from Canada (one out of one), Italy (three out of four) and UK (three out 
of eight). 
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Table 3.8 Number of prototype-like variants among Hong Kong and overseas 
isolates. 
_ … ，、 No. of prototype-like isolates 
Country (No. tested) — 
E6 E7 L I E6, E7 and L I 
HK(132) 9 10 13 9 
Taiwan (10) 0 0 0 0 
Korea (21) 1 1 0 0 
Italy (4) 3 3 3 3 
Argentina (1) 1 1 0 0 
Canada (1) 1 1 1 1 
UK (8) 5 7 5 3 
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3.2.3 HPV52 E6 
3.2.3.1 Sequence variation of E6 ORF 
The HPV52 prototype (GenBank accession number: X74481) was used as the 
reference for comparison. Altogether, 21 different nucleotide sequence variations 
were found within the E6 region (Table 3.9). Thirteen were found only in Hong Kong 
women isolates, while four found only in overseas isolates. The nucleotide variation 
at nt350G>T and nt379A>G (K93R) were the two most common nucleotide 
variations found in both Hong Kong and overseas isolates. The maximum number of 
nucleotide sequence variations for any variant over the 546-bp E6 gene was five 
(1.1%). 
Seven of the 21 nucleotide substitutions were nonsynonymous resulting in 
predicted amino acid changes. The lysine to arginine (K93R) substitution at 
nt379A>G was the most common. Frameshift mutations derived from insertion or 
deletion of nucleotide(s) and premature stop codon were not observed. 
O f the Hong Kong isolates, nine (6.8%) showed complete nucleotide sequence 
homology to the prototype over the entire E6 region, and were regarded as 
'prototype-like' (Table 3.8). For the remaining, 18 E6 Hong Kong variants were 
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identified, and were named according to their frequencies of occurrence as 
HPV52-E6-HK-1 to HPV52-E6-HK-18, of which HK-1, -2 and -3 were the most 
common. The nucleotide sequence variations and their predicted amino acid 
substitutions for each variant are shown in Figure 3.10. Variants found only in 
overseas isolates were also named according to the frequency of occurrence as 
HPV52-E6-non-HK-l to HPV52-E6-non-HK-4. A l l the sequence variations are 
shown in Appendix I and II. 
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Table 3.9 Nucleotide and amino acid substitutions in HPV52 E6 variants 
, • . No. (%) of isolates 
Nucleotide, Ammo acid — 
substitution HongKong Overseas 
( N - 132) ( N - 45) 
n t l T l O G , H24D 0 2 (4.4) 
nt l77A>G, 126 V 2 (1.5) 0 
ntl94G>C, synonymous 1 (0.8) 0 
nt219A>C, synonymous 1 (0.8) 0 
nt220G>T, R40I 1 (0.8) 0 
nt237C>T, synonymous 1 (0.8) 0 
nt251A>G, synonymous 0 1 (2.2) 
nt294A>G, synonymous 1 (0.8) 0 
nt317G>A, synonymous 0 1 (2.2) 
nt329T>C, synonymous 1 (0.8) 0 
nt347A>G, synonymous 1 (0.8) 0 
nt350G>T, synonymous 122 (92.4) 31 (68.9) 
nt356G>A, synonymous 12 (9.1) 1 (2.2) 
nt376T>A, synonymous 0 1 (2.2) 
nt378A>C, K93R 9 (6.8) 0 
nt379A>G, K93R 119 (90.2) 30 (66.7) 
nt391G>C, S97T 2 (1.5) 0 
nt446A>G, synonymous 1 (0.8) 0 
nt467C>A,N122K 8 (6.1) 0 
nt530A>G, synonymous 3 (2.3) 2 (4.4) 
nt531C>G, synonymous 1 (0.8) 0 
nt, nucleotide position according to HPV52 prototype (GenBank accession number: X74481). 
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. N o . o f Pred ic ted a m m o acid 
H P V 5 2 Va r i an t 
isolates b! Ij；； ^ ^ subst i tu t ion 
O ON 00 VO ^ 
Pro to type G G A A C 
H P V 5 2 - E 6 - H K - 1 89 T - - G - K 9 3 R 
H P V 5 2 - E 6 - H K - 2 11 T A - G - K 9 3 R 
H P V 5 2 - E 6 - H K - 3 6 T - C G A K 9 3 R , N 1 2 2 K 
F i g u r e 3 . 1 0 N u c l e o t i d e a n d a m i n o a c i d s u b s t i t u t i o n s a t E 6 o p e n r e a d i n g f r a m e 
o f t h r e e c o m m o n h u m a n p a p i l l o m a v i r u s ( H P V ) 5 2 v a r i a n t s 
HPV52 prototype (GenBank accession number: X74481) as reference. Nucleotide positions are 
written vertically across the top. Positions at which no variations were found are marked with dashes, 
a normal letter indicates a synonymous substitution and a bold letter represents a non-synonymous 
substitution. The one letter amino acid code is used. Position of amino acid changes are stated 
numerically. The letter preceding this number refers to the reference amino acid, and the letter 
following refers to its substitution. 
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3.2.3.2. HPV52 E6 variants and risk for cervical neoplasia 
The frequency of each nucleotide substitution and amino acid substitution 
among various levels of cervical neoplasia was analyzed to assess their possible risk 
association for cervical neoplasia. Table 3.10 shows the distribution of the four most 
common nucleotide substitutions and amino acid substitutions according to the 
degree of cervical neoplasia of Hong Kong isolates, and the odds ratios for invasive 
cervical cancer versus normal. The asparagine to lysine (N122K) substitution at 
nt467C〉A showed a significant positive risk for invasive cervical cancer with a 
P-value of 0.009 by Fisher's exact test (Table 3.10). 
Table 3.11 shows the distribution of the two most common HPV52 E6 variants 
according to the degree of cervical neoplasia and the odds ratios for invasive cervical 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.4 HPV52 E7 
3.2.4.1 Sequence variation of E7 ORF 
Altogether, 22 different nucleotide sequence variations were found within the E7 
region (Table 3.12). Twelve were found only in Hong Kong isolates. The nucleotide 
variation at nt751C>T and nt801A>G were the two most common nucleotide 
variations found in both Hong Kong and overseas isolates. The maximum number of 
nucleotide sequence variations for any variant over the 300-bp E7 gene was nine (3%), 
which shows a higher nucleotide sequence variation than E6. 
Twelve of the 22 nucleotide substitutions were nonsynonymous resulting in 
predicted amino acid changes. Frameshift mutations derived from insertion or 
deletion of nucleotide(s) and premature stop codon were not observed. 
Ten (7.6%) of the Hong Kong isolates showed complete nucleotide sequence 
homology to the prototype over the whole E7 region, and were regarded as 
‘prototype-like，(Table 3.8). For the remaining, six E7 HK variants were identified, 
and were named as HPV52-E7-HK-1 to HPV52-E7-HK-6, of which HK-1 and -2 
were the most common. The nucleotide sequence variations and their predicted amino 
acid substitution for each variant are shown in Figure 3.11. Isolates from overseas are 
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also named according to the frequency of occurrence as HPV52-E7-HK-1 to 
HPV52-E7-HK-2. A l l the sequence variations are shown in Appendix I I I and IV. 
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Table 3.12 Nucleotide and amino acid substitutions in HPV52 E7 variants 
Nucleotide, amino acid No. (%) of isolates 
substitution Hong Kong Overseas 
( N - 132) ( N - 45) 
nt571A>G, T7A 1 (0.8) 0 
nt571T>A, synonymous 5 (3.8) 2 (4.4) 
nt571T>C, K9T 1 (0.8) 0 
nt578A>C, synonymous 1 (0.8) 0 
nt595C>T, synonymous 2 (1.5) 0 
nt662C>T, T37I 5 (3.8) 2 (4.4) 
nt693A>C, synonymous 1 (0.8) 0 
nt696A>T, E48D 1 (0.8) 0 
nt706A>G, synonymous 5 (3.8) 2 (4.4) 
nt707G>A, S52D 5 (3.8) 2 (4.4) 
nt727T>G, Y59D 5 (3.8) 2 (4.4) 
nt733C>T, H61Y 5 (3.8) 2 (4.4) 
nt742G>A, D64N 5 (3.8) 2 (4.4) 
nt748A>G, T66A 1 (0.8) 0 
nt750A>T, synonymous 1 (0.8) 0 
nt751C>T, synonymous 116 (87.9) 30 (66.7) 
nt754C>A, synonymous 1 (0.8) 0 
nt778A<C, T76P 1 (0.8) 0 
nt801A>G, synonymous 121 (91.7) 32 (71.1) 
nt814A>G, T88A 1 (0.8) 0 
nt840T>C, synonymous 1 (0.8) 0 
nt848T>G, L99R 5 (3.8) 2 (4.4) 




























































































































































































































































































































































































































































































































































































3.2.4.2 HPV52 E7 variants and risk for cervical neoplasia 
Table 3.13 shows the distribution of the two most common HPV52 E7 variants 
according to the degree of cervical neoplasia and the odds ratios for invasive cervical 






























































































































































































































































































































































































































































3.2.5 HPV52 LI 
3.2.5.1 Sequence variation of LI ORF 
Within the L I region 51 different nucleotide sequence variations were identified 
(Table 3.14 and 3.15). Twenty-five were found only in Hong Kong isolates, while 
eight were found only in overseas isolates. The hot spot variations were found 
between nt5972-6218, nt6701-6824, nt6917 and nt7052. The maximum number of 
nucleotide sequence variations for any variant over the 1590-bp L I gene was 12 
(0.75%). 
Seven of the 51 nucleotide substitutions found within the L I ORF were 
nonsynonymous resulting in predicted amino acid changes. Frameshift mutations 
derived from insertion or deletion of nucleotide(s) and premature stop codon were not 
observed. 
Complete nucleotide sequence homology to the prototype over the whole L I 
region was regarded as 'prototype-like'. Thirteen (9.8%) of the Hong Kong isolates 
were found to be prototype-like (Table 3.8). For the remaining 119 isolates, 33 L I 
variants were identified, and were named according to their frequencies of occurrence 
as HPV52-L1-HK-1 to HPV52-L1-HK-33, of which, HK-1 to -4 were the most 
95 
common. The nucleotide sequence variations and their predicted amino acid 
substitution for each variant are shown in Figure 3.12. Variants found only in isolates 
from overseas were named according to the frequency of occurrence as 
HPV52-L l -non-HK- l to HPV52-Ll-non-HK-10. A l l the sequence variations are 
shown in Appendix V and VI . 
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Table 3.14 Synonymous nucleotide substitutions in LI variants 
Nucleotide No. (%) of isolates 
substitution ~ “ “ 
Hong Kong Overseas 
(N= 132) (N= 45) 
nt5771A>G 106 (80.3) 26 (57.8) 
nt5801A>G 1 (0.8) 0 
nt5828A>G 2 n . 5 ) 0 
nt5843G>A 1 (0.8) 0 
nt5909A>G 5 (3.8) 2 (4.4) 
n t 5 9 3 9 A � G 1 (0.8) 0 
nt5940A>C 1 (0.8) 0 
nt5960A>G 3 (23) 0 
nt5972T>C 110 (83.3) 27 (60) 
nt6039G>A 2 (\.5) 0 
nt6083G>A 4 (3.0) 2 (4.4) 
nt6110G>A 114 (86.3) 28 (62.2) 
nt6131A>G 1 (0.8) 0 
nt6218G>A 119 (90.2) 30 (66.7) 
nt6221C>A 1 (O.S) 0 
nt6293A>G 1 (0.8) 1 (2.2) 
nt6356G>A 1 (0.8) 0 
nt6425A>G 1 (0.8) 0 
nt6443C>T 5 f3.8) 2 (4.4) 
nt6485A->G 1 (0.8) 1 (2.2) 
nt6587G>A 3 (2.3) 0 
nt6605G>T 1 (0.8) 0 
nt6698G>A 5 (3.8) 2 (4.4) 
nt6701T>G 114 (86.3) 28 (62.2) 
nt6764T>C 110 (83.3) 28 (62.2) 
nt6794A>G 113 (85.6) 27 (60) 
nt6800A>C 0 1 (2.2) 
n t 6 8 2 4 C � T 114 (86.3) 28 (62.2) 
nt6833G>A 1 (0.8) 0 
nt6881C>G 1 (O.S) 0 
nt6897G>C 1 (O.S) 0 
n t6917C�A 119 (90.2) 29 (64.4) 
nt6917C>G 0 1 (2.2) 
nt6920C>G 1 (0.8) 0 
nt6935T>A 0 1 (2.2) 
nt6935T>C 2 (1.5) 0 
nt6941A>G 1 (0.8) 0 
nt6953A>C 0 1 (2.2) 
nt7010A>G 2 (\.5) 0 
nt7052G>A 115 (87.1) 29 (64.4) 
nt7109A>G 0 1 (2.2) 
nt7112G>A 4 (3.0) 1 (2.2) 
nt7133G>A 0 1 (2.2) 
nt7136G>A 1 (0.8) 0 
nt, nucleotide position reference according to HPV52 prototype (GenBank accession number: X74481). 
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Table 3.15 Non-synonymous nucleotide and amino acid substitutions in LI 
variants 
Nucleotide, amino acid No. (%) of isolates 
substitution Hong Kong Overseas 
(N= 132) (N=45) 
nt5578T>C, L5S 5 (3.8) 2 (4.4) 
nt5928C>G, P122A 1 (0.8) 0 
nt6172C>A, P203L 1 (0.8) 0 
nt6184A>C, N207T 2 (1.5) 0 
nt6185T>C, N207T 1 (0.8) 0 
nt6832A〉C, K423T 0 1 (2.2) 
nt7150G>A, R529K 0 2 (4.4) 


















































































































































































































































































































































































































































































































































































































































































































































3.2.5.2 HPV52 LI variants and risk for cervical neoplasia 
The frequency of each nucleotide substitution and amino acid substitution 
among various levels o f cervical neoplasia was analyzed to assess their possible risk 
association for cervical neoplasia. Table 3.16 shows the distribution of the ten most 
common nucleotide substitutions within the L I regions according to the degree of 
cervical neoplasia of Hong Kong isolates and the odds ratios for invasive cervical 
cancer versus normal. No significant risk association was observed. 
Table3.17 shows the distribution of the four most common HPV52 L I variants 
according to the degree of cervical neoplasia and the odds ratios for invasive cervical 
cancer versus normal. Prototype-like variants showed a significant lower risk for 
cervical neoplasia I I I and invasive cervical cancer with an odds ratio of 0.09 (95% 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.6 HPV52 long control region (LCR) 
3.2.6.1 Sequence variation of LCR 
Sixty-five different nucleotide substitutions, four deletions and an insertion 
were found within the LCR region (Table 3.19 and 3.20). Sixteen nucleotide 
substitutions were found only in Hong Kong isolates, while 15 were found only in 
overseas isolates. A l l deletions were found in both Hong Kong and overseas isolates. 
One insertion was found in one of the overseas isolate. The hot spots of nucleotide 
variations were located at nt7168, nt7207, nt7371, nt7622-7659, nt7712 and 
nt7861-7865. The maximum number of nucleotide sequence variations for any 
variant over the 889-bp LCR region was 20 (2.3%). 
Several nucleotide variations were found impacting one or more putative 
transcription factor binding sites. Table 3.21 shows eight o f the putative transcription 
factor binding sites where one or more sequence variations were found among the 
isolates. 
Of the Hong Kong isolates, only two (1.5%) showed complete nucleotide 
sequence homology to the prototype over the whole LCR region, and were regarded 
as 'prototype-like'. For the remaining, 39 LCR Hong Kong variants were identified, 
104 
and were named according to their frequencies of occurrence as HPV52-LCR-HK-1 
to HPV52-LCR-HK-39, of which, HK-1 to -5 were the most common. The 
nucleotide sequence variations for each variant are shown in Figure 3.13. Variants 
found only in isolates from overseas were named according to the frequency of 
occurrence as HPV52-LCR-non-HK-l to HPV52-LCR-non-HK-12. A l l the sequence 
variations are shown in Appendix V I I and VII I . 
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Table 3.19 Nucleotide substitutions in HPV52 LCR variants 
No. (%) of isolates 
Nucleotide substitution — 
Hong Kong Overseas 
(N= 132) (N= 45) 
nt7165C>A 0 1 (2.2) 
nt7166C>A 0 1 (2.2) 
nt7168T>G 0 1 (2.2) 
nt7169T>G 0 1 (2.2) 
nt7170G>T 0 1 (2.2) 
n t 7 1 7 n > G 0 1 (2.2) 
nt7168G>C 115 (87.1) 29 (64.4) 
nt7190G>A 1 (0.8) 0 
nt7207C>A 115 (87,1) 29 ( 6 4 . 4 ) ‘ 
nt7289C>A 0 1 (2.2) 
n t 7 3 7 1 G � T 115 (87.1) 29 (64.4) 
nt73931>C 5 (3.8) 2 (4.4) 
nt7395G>A 0 1 (2.2) 
nt7414T>C 5 (3.8) 2 (4.4) 
nt7416C>T 1 (0.8) 0 
nt7421G>A 5 (3.8) 2 (4.4) 
nt7428A>C 1 (0.8) 0 
n t7509C�G 1 (0.8) 0 
nt7549A>C 1 (0.8) 1 (2.2) 
nt7558G>A 0 0 1 (2.2) 
nt7580A>C 6 (4.5) 2 (4.4) 
nt7586G>A 0 4 (8,9) 
nt7589G>T 0 1 (2.2) 
nt7589G>A 1 (0.8) 0 
nt7620A>C 1 (0.8) 0 
nt7622G>A 120 (90.9) 31 (68.9) 
nt76241>G 116 (87.9) 30 (66.7) 
nt7624T>C 4 (3.0) 3 (6.7) 
nt7657A>C 115 (87.1) 29 (64.4) 
nt7659T>C 120 (90.9) 31 (68.9) 
nt7665G>A 1 (0.8) 0 
nt7671C>T 5 (3.8) 2 (4.4) 
nt7693G>A 5 (3.8) 2 (4.4) 
nt7694A>C 1 (0.8) 1 (2.2) 
nt76%T>C 5 (3,8) 2 (4.4) 
nt7712G>C 119 (90.2) 31 (68.9) 
nt7713G>A 5 (3.8) 2 (4.4) 
nt7743C>T 5 (3.8) 3 (6.7) 
nt7744T>C 0 1 (2.2) 
nt7748A>C 1 (0.8) 0 
nt7773G>T 1 (0.8) 0 
nt7788A>G 5 (3.8) 2 (4.4) 
nt7861G>A 120 (90.9) 31 (68.9) 
nt7863T>G 0 1 (2.2) 
nt7865A>G 113 (85.6) 29 (64.4) 
nt7897G>A 0 1 (2.2) 
nt7911A>C 6 (4.5) 7 (15.6) 
nt7914G>C 1 (0.8) 0 
nt7917C>A 9 (6.8) 2 (4.4) 
nt7931T>G 3 (2.3) 0 
nt7933T>C 31 (23.5) 6 (13.3) 
nt7938A>C 2 (1.5) 1 (2.2) 
nt7938A>G 71 (53.8) 18 (40.0) 
nt7939A>G 1 (0.8) 0 
nt7941T>C 0 1 (2.2) 
ntl3T>C 114 (86.4) 28 (62.2) 
ntl7A>G 1 (0.8) 0 
ntl9T>C 15 (11.4) 9 (20.0) 
nt24A>C 1 (0.8) 0 
nt29T>C 1 (0.8) 1 (2.2) 
nt34T>C 2 (1.5) 1 (2.2) 
nt37A>G 1 (0.8) 0 
nt50C>G 2 (1.5) 0 
ntSOOT 1 (0.8) 1 (2.2) 
nt94G>A 8 (6.1) 1 (2.2) 
nt, nucleotide position reference according to HPV52 prototype (GenBank accession number: 
X74481). 
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Table 3.20 Deletions and insertions among HPV52 LCR variants 
No. (%) of isolates 
Nucleotide variation 
Hong Kong Overseas 
(N= 132) (N=45) 
Deletion 
Del7176 CTGT 0 1 (2.2) 
Del7286 TG 115 (87.1) 29 (64.4) 
Del7386 TTATG 130 (98.5) 42 (93.3) 
Del7697 CTT 120 (90.9) 32 (71.1) 
Insertion 
Ins7212 
CTATGTGTTGTGTATGTC 0 1 (2.2) 
AAACACAGGTTA 
Del, deletion; Ins. insertion. The number after indicates the nucleotide position where 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.6.2 HPV52 LCR variants and risk for cervical neoplasia 
The frequency of each nucleotide substitution and changes in putative 
transcription factor binding sites among various levels of cervical neoplasia was 
analyzed to assess their possible risk association for cervical neoplasia. Table 3.21 
and 3.22 show the distribution of the common nucleotide substitutions and putative 
transcription factor binding site variations according to the degree of cervical 
neoplasia of Hong Kong isolates and the odds ratios for invasive cervical cancer 
versus normal. The nucleotide substitution at nt7938A>G showed a significant lower 
risk for invasive cervical cancer with an odds ratio of 0.14 (95% confidence interval 
二 0.03-0.61, P = 0.002) relative to control (Table 3.23).Consistent with this finding, 
isolates with nucleotide changes within Oct-1 binding site at nt7933-7945 also 
showed a significant lower risk for invasive cervical cancer with an odds ratio of 
0.14 (95% confidence interval 二 0.03-0.61, P = 0.002). 
Table 3.23 shows the distribution of the six most common HPV52 LCR variants 
according to the degree of cervical neoplasia and the odds ratios for invasive cervical 
cancer versus normal. HPV52-LCR-HK-4 showed a significant higher risk for 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1 HPV prevalence and type distribution 
Cervical cancer is the second most common cancer of women worldwide, and it 
is widely accepted that HPV infection is a necessity for the development of cervical 
cancer. The study on the epidemiology of HPV infection allows the development of 
strategies for the prevention of cervical cancer. 
4.1.1 HPV prevalence 
The age-standardized incidence rate of cervical cancer in Hong Kong is 12.6 
cases per 100,000 women in 2004 according to the Hong Kong Cancer Registry, 
which is slightly higher than the average world age-standardized cervical cancer 
incidence rate of 9.4 cases per 100,000 women. However, Hong Kong is still regarded 
as a low-risk area compared to other high-risk countries such as Zimbabwe, Brazil 
and Thailand where the age-standardized cervical cancer incidence rate has been 
reported to be 54.3, 38.2 and 25.3 respectively (Parkin et al, 2002). In the current 
study, the overall prevalence of HPV in Hong Kong Chinese population was 6.7%, 
which was similar to countries with a low incidence of cervical cancer, such as The 
Philippines (9%) and Spain (6%) (Ngelangel et al., 1998, Parkin et al., 2002). 
HPV 16, 52 and 58 were the three most prevalent HPV types in the Hong Kong 
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general women population, which was different from the worldwide type distribution, 
of which HPV 16, 18 and 45 were the three most prevalent HPV types among the 
general women population (Munoz et al., 2003). The high prevalence of HPV52 and 
58 was also observed in the general women population of other Asian countries such 
as Taiwan and Korea (Clifford et al., 2005, Lin et al., 2006, Shin et al., 2003). As 
similar to the situation in Hong Kong as revealed by the current study, HPV 16, 52 and 
58 were also the three most prevalent HPV types in the Taiwan general women 
population, and accounted for 63% of all high-risk HPV infections. In the current 
study, these HPV types accounted for 50% of all HPV infections. While HPV 16 and 
18 accounted for only 30% and 25% of all HPV infections in Taiwan and Hong Kong, 
respectively. The high prevalence of HPV52 and 58 suggests that the current 
HPV 16/18 vaccine may not be enough to protect Asian women from HPV52- and 
58-associated cervical cancers. There is a strong need for development of HPV52 and 
58 vaccines. 
Previous studies found that the percentage of multiple HPV infection among 
HPV-positive women ranged from 5.3% in Morocco, 19.6% in Mexico, 31.0% in 
Costa Rica to 44.7% in US (Chaouki et al., 1998, Herrero et al., 2005, Lazcano-Ponce 
et al., 2001, Peyton et al., 2001). The differences in the prevalence may partly be due 
to the difference in genotyping methods used, which may have different sensitivity, 
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specificity, and have different efficacy to reveal multiple infections. The prevalence of 
multiple infections found in the current study was 41 %, of which about 60% harbored 
two HPV types. The sensitive reverse line-blot hybridization method was used for 
genotyping in the current study, which could detect 37 HPV genotypes and also 
multiple infections, thus we observed a high prevalence of multiple infection. 
4.1.2 Age-specific prevalence 
Different patterns of age-specific prevalence for high-risk and low-risk HPV 
were observed in the current study. The prevalence of high-risk HPV infection was the 
highest among young women and then declined with age, and slightly increased at 
46-50 years. For the low-risk HPV infections, a similar curve was obtained, but a 
more obvious second peak was observed at ages 46-55 years. Although many previous 
studies have shown that HPV prevalence declined with increasing age (Franceschi et 
al., 2006, Hassen et al., 2003, Schiffman and Castle, 2003)，a second peak of 
prevalence in women of elder age was observed in other population-based studies in 
Costa Rica, Colombian and Mexico (Castle et al., 2006, Herrero et al., 2005, 
Lazcano-Ponce et al., 2001, Munoz et al., 2004). 
The decline in HPV infection observed at the age group of 31-45 years old may 
be due to the lower exposure to HPV because of a more stable sexual behaviour, as in 
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our current study, about 90% of the participants were married. Another explanation 
could be the acquired immunity to HPV from past exposure at younger ages. 
HPV infections detected in elder women may represent the persistence of 
infections exposed early in life. However, the reasons for the higher HPV prevalence 
in elder age women than women at the age of 31-45 were still unclear. It may be 
explained by women having new sex partners or their husband having extramarital 
sex partners, as it has been reported that HPV infection in wives was associated with 
husband having extramarital sex partners (Sukvirach et al., 2003). However, the 
questions on the sexual behaviour at elder age were not included in the questionnaire 
of our current study. Thus, it is difficult to assess whether these hypotheses are true in 
our population. It may also be due to the cohort effect that these elder age women 
were more heavily exposed to HPV in their early lives (Herrero et al., 2000). However, 
the HPV prevalence data in the earlier decades was not known. 
The other explanation is the reactivation of latent HPV infection due to the 
decrease of immunity in elder age women or due to hormonal changes resulting from 
menopause or hormone replacement therapy (Grainge et al., 2005). However, the 
presence of antibody cannot be used as the indicator of previous HPV infection, since 
not all of the infected individual will develop antibody. Theoretically, if the 
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reappearance of HPV infection at elder age resulted from the same HPV variant that 
the woman was infected earlier in her life, it maybe regarded as reactivation of 
previous HPV infection. However, this kind of study is difficult to perform, as the 
individual needed to be followed for at least 30 years and with repeated sampling. 
It maybe useful to include questions about the number of sex partners within the 
last two years in the questionnaire. A positive result for HPV for those women who 
reported having no sex partner within the last two years may suggest a persistence 
infection or reactivation of pervious HPV infection. 
The second peak of HPV prevalence was observed notably in low-risk HPV 
rather than in high-risk HPV in studies from Colombia and Costa Rica (Herrero et al., 
2005, Munoz et al., 2004) which was in line with our results. The difference may be 
the result of the research design. In our current study, we recruited women attending 
the cervical cancer screening centre; those having any abnormalities will be 
transferred to other clinic for treatment. Within our study population, nearly 70% of 
them were not having the first screening, which represents the group of women 
having normal cervix. Thus, more women with a normal cervix were recruited. This 
may lead to an underestimation of the number of high-risk HPV infections persisted in 
elder women, as more high-risk HPV will persist and the persistent infections may 
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lead to cervical intraepithelial lesions at elder age and were subjected to treatment, 
and thus were not included in the study. However, low-risk HPV infections will 
probably not develop into cervical intraepithelial lesions (Jacobs et al., 2000) and thus 
more non high-risk HPV infections were included in the study. 
However, the difference between the persistence of high-risk and low-risk HPV 
cannot fully explain their difference in the prevalence patterns. As the U-shaped 
prevalence pattern was also observed in high-risk HPV in Taiwan and Mexico 
(Lazcano-Ponce et al., 2001, Lin et al., 2006). Different prevalence patterns were 
observed for the six most common oncogenic HPV types in the current study. The 
prevalence of HPV 16, 18 and 51 peaked at young age and declined with increasing 
age, whereas there was a minor peak at age 46-55 years for HPV33, 52 and 58. 
A study in Costa Rica suggests that the difference in prevalence patterns was 
associated with the infection of HPV types with different species, rather than 
oncogenicity, which may have different tropism for the target cell types (Castle et al., 
2006). Castle et al. found that the prevalence of HPV alpha-9 species was the highest 
in the youngest women, and a second minor peak has observed in women ages 55-64 
years. However, the prevalence of the alpha-3 and -15 species had the tendency to 
increase with increasing age, and was peaked at women with age over 55. They 
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suggested that vaginal squamous epithelial cells may be more susceptible to the 
infection of aIpha-3 and -15 species than squamous metaplasia epithelial cells of the 
cervical transformation zone. Due to the age-related physiological changes of the 
cervix, different cells are collected in the specimens obtained from the cervical os. 
More vaginal squamous epithelial cells are collected in the cervical scrape samples of 
elder women than in younger women. Thus, more HPV of alpha-3 and -15 species 
were detected in the elder women. This finding was somehow consistent with our 
results that we also observed a major peak for alpha-3 species (contain mostly 
low-risk HPV types) in women of 46-55 years, but not for alpha-5, -7 and -9 species 
(contain mostly high-risk HPV types). However, unlike the study of Castle et al., a 
first peak for alpha-3 species was observed in younger women ages 26-30 years. In 
our current study, a similar pattern of prevalence was observed in alpha-3 and -6 
species, which suggested the possibility of HPV alpha-6 species having the same cell 
type tropism as alpha-3 species. However, further investigation is needed. 
More evidence is needed to confirm the differences in viral tropism of different 
HPV species. However, this suggests that the lower oncogenicity in HPV types such 
as the alpha-3, -6 and -15 species may be due to their lower tropism for the cervical 
cancer-susceptible cells present at the squamous-columnar junction. 
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4.1.3 Epidemiological risk profile 
Different patterns of prevalence were observed for the high-risk, low-risk, 
alpha-3/-6 and alpha-5/-7/-9 HPV groups, and the risk factors for these HPV groups 
were analyzed separately. 
Age and the number of sex partners were found to be the main determinants for 
HPV infections in many previous population-based studies (Herrero et al., 2005, 
Lazcano-Ponce et al., 2001，Munoz et al., 2004, Peyton et al., 2001). A negative 
association with age was found in all HPV groups in the current study, except for the 
low-risk HPV group. The different association with age of high-risk and low-risk 
HPV types was also observed in previous studies (Kjaer et al., 1997,Munoz et al., 
2004)，and the difference was also reflected in the different prevalence patterns 
observed for high-risk and low-risk HPV groups. 
Previous studies have reported the association of sexual behaviour and HPV 
infection (Herrero et al., 2005, Lazcano-Ponce et al., 2001, Munoz et al., 2004), which 
provides evidence for the sexual transmission of HPV. Increased risk for HPV 
infection with increasing number of lifetime sex partners and younger age (<18 years) 
at first sexual intercourse was observed in the age-adjusted analysis in the current 
study, which was consistent with previous studies, which further reinforce the sexual 
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transmission of HPV. However, the association with the age at first sexual intercourse 
was not significant when it was subjected to multivariate analysis. This suggested that 
the effect of younger age at first sexual intercourse maybe confounded by having more 
sex partners. Increasing number of sex partners was found only significant in 
multivariate analysis for the low-risk HPV and alpha-3 and -6 HPV groups. However, 
a trend of increasing prevalence of HPV infection with increasing number of sex 
partners was observed in all HPV groups. The reason for the lack of a significant 
association may be due to the small number of women having two or more sex 
partners, as nearly 85% of them reported only one lifetime sex partner. It has been 
reported that there was a significant association between the risk of HPV and the 
number of partners in the last year but no association with lifetime number of sexual 
partners (Svare et al., 1998). However, we could not assess if it was the case in our 
population as the question on recent sex partners was not included in the 
questionnaire. 
The difference in risk profile between the low-risk and high-risk groups may be 
the result of the different sexual behaviour of their partners, as many studies had 
confirmed that male sexual behaviour is the central determinant of the incidence of 
HPV infection and cervical cancer in female (Kjaer et al., 1991, Skegg et al., 1982, 
Thomas et al., 2001). Thus, it is better to include the sexual behaviour of the male 
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par tners in the analys is . 
The findings for the association of smoking and HPV infection were inconsistent. 
Some studies showed that smoking was independently associated with increased risk 
for cervical neoplasia (Szarewski et al., 1996), while others did not find an association 
between them (Lazcano-Ponce et al., 2001, Munoz et al., 2004). In the current study, 
it was found that smoking was an independent risk factor for any-type, high-risk and 
alpha-5, -7 and -9 HPV groups, even after adjusted for sexual behaviour, and it was 
confirmed by the positive association of having a smoker in family with the risk for 
HPV infection in all HPV groups. This suggests that smoking behaviour, both active 
and passive, is associated with persistent HPV infections. It is also supported by a 
study which suggested that the mutagenic activity of cigarette components may 
contribute to the persistence of HPV or to malignant transformation in cervical cells 
(Yang et al., 1996). 
The significance of protective effect of barrier contraception has been 
inconsistent among the previously published studies. A meta-analysis has shown that, 
the use of condom conferred protection against cervical lesions but not HPV infection 
(Manhart and Koutsky, 2002). However, another population-based study has shown 
that barrier contraception conferred a strong protection against HPV infection (de 
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Sanjose et al., 2003). A recent study followed 82 female university students who 
reported their first intercourse during the study period or within two weeks before 
study (Winer et al., 2006). The students were followed for an average of 34 months, 
with gynecologic examinations performed every four months. It was found that the 
adjusted hazard ratio was 0.3 (95% confidence interval = 0.1-0.6) for women whose 
partners used condoms for all instances of intercourse. This study provides strong 
evidence that consistent condom use of male partners reduces the risk of cervical HPV 
infection among newly sexually active women. In our study, the regular use of barrier 
contraceptives was shown to have a protective effect for the any-type HPV group in 
the age-adjusted analysis. However, the association became not significant when 
subjected to multivariate analysis. 
Long-term use of oral contraceptives has been reported to show increased risk 
for HPV infections in some studies (Hildesheim et al., 1993, Kjaer et al., 1997), but 
not others (Lazcano-Ponce et al., 2001, Munoz et al., 2004). In our study, no evidence 
for the association between long-term use of oral contraceptives and HPV infection 
was observed. 
Our current study showed a positive association between history of treatment for 
cervical lesions and infection with any-type, high-risk and alpha-5, -7 and -9 HPV 
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groups, but not with low-risk and alpha-3 and -6 HPV groups. This is in line with the 
hypothesis that the development of cervical lesions are usually related to infection 
with high-risk HPV types (Jacobs et al., 2000). The positive association also suggests 
that treatment for cervical lesions may not remove all the HPV infection from cervical 
cells, as the virus was still detectable in cervical scrape samples. 
Some of the previous studies have reported a negative association between 
pregnancies and HPV infection (Bauer et al., 1993, Burk et al” 1996, Molano et al., 
2002), while one reported a positive association (Hildesheim et al., 1993). It has been 
suggested that the trauma of birth canal during pregnancy may trigger antigen 
presentation and activating the cellular immune responses, which may control HPV 
infection transiently (Lazcano-Ponce et al., 2001). However, this was contradictory to 
the observation that high parity is one of the main cofactors for the progression to 
cervical intraepithelial neoplasia and invasive cancer (Munoz et al., 2002, Parazzini et 
al” 1989). It is possible that high parity only contributes to the progression of a 
persistent HPV infection to cervical lesions, but will not induce HPV persistence. 
From our current study, we did not observe an association between parity and HPV 
infection, as have been shown in other studies (Peyton et al., 2001, Shin et al., 2003). 
The association between parity and HPV infection remains inconclusive. 
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4.1.4 Conclusions 
In conclusion, the overall prevalence of HPV infection in Hong Kong Chinese 
population was 6.7%, which is similar to countries with a low incidence of cervical 
cancer. HPV 16, 52 and 58 were the three most prevalence HPV types found in Hong 
Kong, which revealed the need for the development of HPV52 and 58 vaccines for the 
prevention of HPV52- and 58-mediated cervical diseases in Hong Kong. 
The age-specific prevalence of HPV infection peaked in the age group of 26-30 
years, and a minor peak was observed in elder women of age 46-55 years. Different 
patterns of age-specific prevalence were observed for the alpha-3, -6 and alpha-5, -7, 
-9 HPV groups. Two peaks were found in young age and elder age for the alpha-3, -6 
HPV groups, whereas, a pattern similar to the overall HPV infection was observed in 
the alpha-5, -7, -9 HPV groups. 
Young age was associated with a higher prevalence of all groups of HPV 
infection except for the low-risk HPV group. Smoking behavior, both active and 
passive, had an independent risk association with HPV infections. Number of lifetime 
sex partners was associated only with low-risk and alpha-3, -6 HPV infections. 
History of treatment for cervical lesions was positively associated with any-type and 
high-risk HPV infection. Number of full-term pregnancies, age at first sexual 
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intercourse, use of barrier contraception and oral contraception did not have 
independent association with HPV infection. 
4.2 HPV 52 sequence variation 
HPV52 are more commonly found in Hong Kong and other Asian countries than 
elsewhere in the world. For this reason, we focused on the sequence variations of the 
Hong Kong HPV52 variants and examined their association with cervical 
intraepithelial neoplasia and invasive cancer. 
4.2.1 Sequence variability of HPV52 
We sequenced the E6, E7, LI and LCR regions of 132 Hong Kong 
HPV52-positive samples and 45 overseas HPV52-positive samples. The sequences 
were compared with HPV52 prototype (GenBank accession number: X74481). It was 
found that the LI open reading frame was the most conserved region, followed by E6, 
LCR and E7, with the maximum sequence variations of 0.8%, 1.1%, 2.3% and 3%, 
respectively. Our finding is in line with other studies on HPV 16 and HPV 18, with LI 
being the most conserved region (Arias-Pulido et al., 2005, Yamada et al., 1995). 
Until now, only one study on the sequence variations of different gene regions 
among HPV52 has been reported (Aho et al., 2003). In that study, HPV52 E6, E7 and 
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LCR regions were sequenced and compared with the prototype. In consistence to our 
finding, Aho et al. also observed a higher variability for E7 in comparison to E6 in 
HPV52 isolates. A similar result was also observed in HPV58 (Chan et al., 2002a). 
However, many studies on HPV 16 have shown that E6 is more variable than E7 
(Stephen et al., 2000, Zehbe et al., 1998). This difference suggests a different pattern 
of gene variability among HPV of different types, and a higher variability in E7 gene 
was observed in HPV52 and 58. 
In our study, E7 was the most variable region among HPV52. In contrast to our 
findings, a study from the United States showed that LCR was the most variable 
region among HPV 16, with a maximum sequence variations of 4.9% (Yamada et al” 
1995). However, only the 3' end of the LCR was sequenced in their study, which has 
been shown to be a hypervariable region within the whole LCR (Chan et al., 1992, 
Giannoudis and Herrington, 2001). Thus, it is expected that the overall sequence 
variations of the LCR will be lower. 
Isolates with complete nucleotide sequence homology to the prototype over the 
E6, E7 and LI regions were regarded as prototype-like variants. The sequence 
homology of the LCR was not considered, as the sequences within the LCR were too 
varied. Among the 132 Hong Kong isolates, only 6.8% had the same sequence with 
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the prototype. HPV52 prototype-like variants were rarely found in Hong Kong 
women, but has been reported that white women were more frequently infected with 
prototype than non-prototype HPV52 (Aho et al., 2004). As the HPV52 prototype was 
isolated from United States (Shimoda et al., 1988), it was reasonable to found more 
HPV52 prototype in the white women. 
For our overseas isolates, no prototype sequence was found in the ten Taiwan and 
21 Korea isolates. Prototype-like sequences were found more frequently in the 
isolates from Canada (one out of one), Italy (three out of four) and United Kingdom 
(three out of eight). This may suggest a different geographic distribution of variants. 
However, there were too few isolates from each country, and there may be selection 
bias from different overseas collaborators. Thus, the data may not represent the 
general population; further studies should be performed before drawing any 
conclusion. 
4.2.2 Sequence variation of E6 gene 
E6 and E7 are oncogenes responsible for the transforming ability of HPVs, 
variations within the E6 and E7 genes may alter the risk of malignant transformation. 
Available studies are almost exclusively on HPV 16, while only a limited number of 
studies have addressed HPV52. Many studies have described an HPV 16 variant with a 
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nucleotide (nt) substitution of T to G at position 350, causing the amino acid 
substitution of leucine to valine (L83V) to be associated with viral persistence and 
progression to invasive cervical disease (Londesborough et al., 1996, Zehbe et al., 
1998). Chakrabarti et al. demonstrated that the association of variant L83V and 
cervical cancer was due to its enhancement of mitogen-activated protein kinase 
(MARK) signaling and deregulation of Notch 1 signaling (Chakrabarti et al., 2004). 
On the other hand, it has been shown that no HPV 16 variant was associated with 
higher risk of cervical cancer in the German population (Nindl et al., 1999) and Zehbe 
et al. suggested that the oncogenicity of this variant may be determined by the genetic 
differences in different populations (Zehbe et al., 1998). In view of these studies, 
another group of scientists investigated the role of the p53 codon 72 polymorphism 
with HPV 16 variants status, and described a higher susceptibility of p53 Arg allele to 
HPV 16 83V-mediated carcinogenesis. However, a larger population-based study is 
needed before arriving at any conclusion (van Duin et al., 2000). The L83V variant 
was not found in the current study, but the same mutation was observed in one HPV52 
isolate in a study performed on Canadian women (Aho et al., 2003). 
In our study, the risk association for cervical cancer was analyzed on the variants 
found in 132 Hong Kong isolates only, but not for the 45 overseas isolates. The host 
factors such as HLA type may also affect the risk association (Cuzick et al., 2000) 
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since the oncogenicity of variant has been shown to be determined by the genetic 
differences in different populations (Zehbe et al., 1998). Due to these reasons we did 
not pool the overseas samples with local samples for risk analysis. Furthermore, the 
pathology status for 12 of the overseas samples was not known, thus their risk 
association for cervical cancer could not be investigated. 
In our study, variation with amino acid substitution from asparagine to lysine at 
amino acid (aa) 122 was obtained in eight of the Hong Kong isolates，which was 
associated with a much higher risk for cervical cancer (P-value of 0.009 by Fisher's 
exact test). The N122K substitution was found only in one HPVS2 isolate in another 
study and the risk association was not analyzed (Calleja-Macias et al., 2005). Since 
the N122K substitution was not the only amino acid substitution present in the 
isolates and these isolates may have different make up of nucleotide substitutions. 
Thus, the higher risk of these isolates may be a result of the combine effects of all the 
nucleotide substitutions presented, and it is better to include only isolates having the 
same nucleotide substations for analysis. The functional implications of the amino 
acid substitution needed further investigation to confirm its risk for cervical cancer. 
However, its increased risk for cervical cancer maybe related to the binding of E6AP, 
as it was suggested that the region involved in E6AP binding was between amino acid 
121 and 128 (Liu et al., 1999, Nomine et al., 2006). 
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4.2.3 Sequence variation of E7 gene 
E7 protein consists of an extremely hydrophilic N-terminal domain and a more 
hydrophobic C-terminal. The structure and function of E7 of HPV is related to other 
viral proteins in DNA viruses such as simian virus large tumor antigen (SV40 Tag) 
and adenovirus ElA (Ad ElA) protein (Vousden and Jat, 1989). The E7 protein is 
divided into three domains according to the homology with Ad ElA, the conserved 
region one (CRl), conserved region two (CR2) and conserved region three (CR3). In 
HPV 16, the E7 CRl consists of amino acid 1-20; CR2 consists of amino acid 21-38, 
which contains a Leu-X-Cys-X-Glu domain for binding with the tumor suppression 
protein pRB and its related proteins, pi03 and pi30 (Davies et al., 1993,Dyson et al., 
1989). CR2 also contains casein kinase II (CKII) site, which maybe involved in 
transformation (Barbosa et al., 1990). CR3 consists of amino acid 39-98, which 
contains two Cys-X-X-Cys motifs for zinc-binding important for the correct folding 
of the protein (Watanabe et al., 1992). 
The E7 proteins of low-risk types were found to have a lower affinity for pRB. 
Comparison between the CR2 of HPV 16 (high-risk HPV) and HPV6 and 11 (low-risk 
HPV) revealed a difference in amino acid sequence near the pRB binding site: 
aspartic acid (aa 21) was found in HPV 16, while glycine (aa 22) was found in HPV6 
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and 11. With the substitution of a glycine to aspartic acid of aa22 in HPV6, the 
affinity for pRB binding was greatly enhanced (Heck et al., 1992, Sang and Barbosa, 
1992). No change in the aspartic acid at aa21 was observed in our study and it was 
found to be relatively conserved in other HPV types (Stephen et al., 2000, Zehbe et al., 
1998), suggesting its importance on HPV oncogenicity. 
It has been reported that a nucleotide change at nt647 in HPV 16 resulted in an 
amino acid substitution from asparagine to serine at aa29. This mutation was 
associated with invasive cancer, and was proposed to create an additional CKII 
phosphorylation site (Song et al., 1997). Another study in Taiwan investigated the 
binding affinity of E7-pRB of HPV 16 using the yeast two-hybrid system. A drop of 
binding affinity to pRB was observed in variants containing the amino acid 
substitution of C24W (Choo et al., 2000). However, no such variations were observed 
in our HPV52 isolates. 
Most of the isolates (146 out of 177) examined in the current study contained 
only synonymous nucleotide variations. For the eight isolates with amino acid 
substitutions, nine out of 12 amino acid substitutions were located in CR3, only the 
substitution of T37I at nt662 was found in CR2, which did not impact on the pRB 
binding site nor CKII site, and was consistent with the findings of Aho et al. (2003). 
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No significant association with increased or decreased risk for cervical cancer was 
observed among the Hong Kong isolates. 
4.2.4 Sequence variation of LI gene 
LI is the major capsid protein, which is the target of neutralizing antibody 
responses (Dillner et al., 1995, Kirnbauer et al., 1992). Any changes in the sequence 
may affect the conformation-dependent epitopes and interfere with the antigenic 
properties of the virus, which may affect the persistency of the viral infection and alter 
the risk for development of cervical diseases. It was reported that a single amino acid 
change from aspartic acid to histidine at aa202 of LI protein in HPV 16 caused the LI 
proteins to assemble into virus-like particles (VLPs) with a 3-fold higher efficiency, 
as compared to the HPV 16 prototype (Kirnbauer et al., 1993). Another study observed 
that the yield of VLPs produced in cell expression system varied in HPV 16 variants 
with a single amino acid variation at aa83 to 97 (Touze et al., 1998). These studies 
suggest that a single alternation of amino acid within the LI protein may result in 
significant differences in the efficiency of LI expression. 
Up to now, only one study on HPV52 LI sequence variations has been reported, 
where two nonsynonymous nucleotide variations K380T and S383D were observed in 
an HPV52 isolate (Calleja-Macias et al., 2005). In the current study, these two amino 
134 
acid substitutions were not found, rather, six novel nonsynonymous nucleotide 
variations were observed. The functional implications of these amino acid changes 
need further investigations. 
A lower risk for CIN III and invasion cancer was observed for the LI 
prototype-like variants with the odds ratios of 0.09 (95% confidence interval = 
0.00-0.86). However, currently no other studies on the risk association of LI variant 
and cervical cancer has been published, therefore whether this protective outcome is a 
result of the phenotype of the LI protein or due to other genes and the corresponding 
actions on oncogenicity need further investigations. Studies involving larger 
population should be of advantage to further confirm our findings. 
4.2.5 Sequence variation of LCR 
The transcriptions of HPV E6 and E7 oncogenes are regulated by the early 
promoter, enhancer and silencer located in the LCR. The enhancer located in the 
middle part of the LCR is epithelial-specific, and contains several binding sites for 
transcription factors, such as nuclear factor 1 (NFl), activating protein-1 (AP-1) and 
octamer-binding factor-1 (Oct-1) (Chen et al., 2005, Desaintes and Demeret, 1996, 
Liu et al., 2002). The silencer element is located near the early promoter and is 
down-regulated by the transcription factor YYl (Bauknecht et al., 1992). Variations 
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within LCR may cause changes in binding affinity for transcription factors, and thus 
their transcriptional activities. 
AP-1 is one of the key players for the epithelial-specific and differentiation 
dependence of the transcriptional activity of the LCR. Increased binding activity has 
been observed in the differentiating mouse keratinocytes, which was induced by the 
activation of protein kinase C (PKC) that also regulate calcium signal for cell 
differentiation (Rutberg et al., 1996). During the host cell differentiation, AP-1 binds 
to LCR enhancer in higher efficiency and thus raises the E6/7 promoter activity. It 
was reported that an induced point mutation within the LCR, impacting an AP-1 
binding site, from an HPV 16 immortalized human oral cancer cell line increased the 
binding affinity of AP-1 to LCR, and stimulated the E6/7 promoter activity (Liu et al., 
2002). This finding suggests the importance of AP-1 on HPV-mediated 
carcinogenesis. Variations impacting an AP-1 binding site (nt 7689-7700) were 
observed in most of the HPV52 isolates (90.9%). However, no risk association for 
cervical cancer was observed, which was in line with the study of Aho et al. (2003). 
YY-1 acts as a repressor for transcription, and is found in nearly all HPV types. 
In HPV 16, YYl binding sites are found located near to the API binding sites, which 
suggests the YYl-mediated repression may be resulted from the quenching of the 
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activity of API. It has been suggested that YYl bind to the coactivator 
(CREB-binding protein) of API in order to repress it action (O'Connor et al., 1996). 
Variations impacting the YYl sites in HPV 16 LCR were found commonly in cancer 
samples with enhanced promoter activity (May et al., 1994). No variations impacting 
the YYl binding site was observed in the current study, consistent with the other 
study on HPV52 (Aho et al., 2003). 
The CCAAT/enhancer binding protein factors (C/EBP) contain a basic zipper 
motif for DNA binding and protein dimerization. It is also known as NF-IL6 because 
it was first identified as a nuclear factor for the expression of interleukin 6. The 
C/EBP sites overlapped with the binding sites for NF-1 and AP-1, and have a 
repressive effect upon the competition with AP-1 for binding (Kyo et al., 1993). Loss 
of putative C/EBP binding sites has been observed in most of the HPV52 isolates of a 
Canadian population. Mutation in the putative C/EBP binding site was also found in 
4.5% of the HPV52 isolates in the current study. However, no risk association for 
cervical cancer was observed, and its significance awaits confirmation by functional 
assays. 
The Oct-1 proteins belong to the family of POU domain proteins which consist 
of a bi-partite motif for the binding to octamer DNA sequence ATGCAAT or 
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degenerate sequence motifs, and were presented in a variety of transcription factors. It 
has been reported that inactivation of octamer binding site of HPV 16 resulted in a 
higher level of gene expression in cells transfected with a human Oct-1. However, a 
lower level of gene expression was observed in cells transfecting cervical-specific 
octamer. This result suggests that the octamer-binding motif acts as positive element 
for gene expression with cervical-specificity (Morris et al., 1993). Another study has 
demonstrated that mutation within the Oct-1 binding site in the 3'-part of the enhancer 
decreased the HPV 16 enhancer activity (O'Connor and Bernard, 1995). This 
phenomenon was also observed in the current study, HPV52 variants with one or 
more nucleotide changes impacting the putative Oct-1 binding site at nt7933-0003 
showed a protective effect against invasive cervical cancer with an odds ratio of 0.26 
(95% confidence interval = 0.08-0.79). This may result in a decrease in transcriptional 
activity upon the disruption of the binding site. However, functional assay should be 
performed to verify the change in promoter activity. HPV52 LCR variants with a 
nucleotide change at nt7938 also showed a lower risk for cervical cancer with an odds 
ratio of 0.32 (95% confidence interval 二 0.10-0.97), which was in line with the 
previous result. 
The HPV52-LCR-HK-4 variant showed a much higher risk for cervical cancer 
with 尸-value of 0.009 by Fisher's exact test. Functional assay such as the Luciferase 
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activity assay should be performed to investigate whether the observed increased risk 
resulted from the alternation in promoter activity. 
In the current study, deletions compared to the prototype were found in over 90% 
of the HPV52 LCR variants. A similar observation was made in another study, and it 
was reported that deletions were more frequently found in HPV52 than in HPV 16 
from the same cohort of women (Aho et al., 2003, Mayrand et al., 2000). 
4.2.6 Conclusions 
In conclusion, the LI region was found to be the most conserved region among 
the four regions examined in HPV52. However, HPV52 E7 was found to be more 
variable than E6, in contrast to HPV 16. HPV52 prototype-like variants were rarely 
found in Hong Kong women. 
This is the first study reporting a higher risk for cervical cancer of HPV52 E6 
N122K variant with a P-value of 0.009 by Fisher's exact test. We found six novel 
amino acid substitutions: L5S, PI22A, 9203L, N207T, K423T and R529K within the 
LI open reading frame. A lower risk for cervical intraepithelial neoplasia III and 
invasion cancer was observed for the LI prototype-like variants with an odds ratio of 
0.09 (95% confidence interval = 0.00-0.86). HPV52 LCR variants with one or more 
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nucleotide changes impacting the putative Oct-1 binding site at nt7933-7945 showed a 
protective effect against invasive cervical cancer with an odds ratio of 0.14 (95% 
confidence interval = 0.03-0.61, which is in line with the reported findings of HPV 16. 
More deletions were found within the HPV52 LCR than HPV 16. 
4.3 Further studies 
In the first part of the current study, we observe the association of sexual 
behaviour and HPV infection. However, the analyses lack the information on the 
sexual behaviour of the male sex partners, which may contribute to the risk of HPV 
infection for the women. Moreover, including the question about the number of recent 
sex partners of women would also provide useful information for further analyses of 
the role of sexual behaviour in HPV infection. 
In the second part of the study, the major limitation of the study is the small 
sample size. It will be of advantage to increase the number of samples so to increase 
the number of each variant for assessing their risk association with cervical cancer in 
the further study. Moreover, both HPV52 single infection and co-infection samples 
were included in the current study, which may affect the analysis for the risk 
association. It is better to include only HPV52 single infection for further risk 
analysis. 
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Differences between HPV52 and the major oncogenic types, HPV 16, and other 
HPV types were revealed in the current study, which suggests different biological 
properties between different HPV types. Thus, previous data derived from HPV 16 
cannot be fully applied in HPV52. Moreover, HPV52 was found to be more prevalent 
in Hong Kong than in other countries. Thus, more studies on HPV52 are needed. 
Further studies can focus on the functional implications of high- or low-risk amino 
acid substitutions in HPV52 variants revealed in this study. It is worthwhile to 
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Appendix I: 
Nucleotide and amino acid substitutions at E6 open reading frame of all Hong 
Kong isolates 
l'roti)(>pc i \ . 
HK-1 C342 - - - - - - 丁 - - - G - - - - - K93R 
HK-1 C361 - - - - - - - - - - - 丁 - - - G - - - - - K93R 
HK-1 C592 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 C596 - - - - - T - - - G K.93R 
HK-1 C623 - - - - - - T - - - G - - - - - K93R 
HK-3 C644 T - - C G - - A - - K93R, N122K 
HK-3 C847 T - - G G - - A - - K93R,N122K 
HK-5 C849 C - - - - - - - T - - C G - - A - - K93R,N)22K 
HK-1 C854 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 Foi l - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 F036 - - - - - - - - - - - T - - - G K93R 
HK-1 F057 - - - - - - - - - - - T - - - G K93R 
HK-1 F082 - - - - - T - - - G - - - - - K93R 
HK-2 F088 T A - - G K93R 
Prototype-like F095 -
HK-2 F099 T A - - G - - - - - K93R 
HK-1 F130 T - - - G - - - - - K93R 
HK-1 F157 T - - G - - - - - K93R 
HK-1 F204 T - - - G K93R 
HK-2 F205 T A - - G - - - - - K93R 
HK-1 F231 - T - - - G - - - - - K93R 
HK-1 F248 - - - - - - T - - - G - - - - - K93R 
HK-1 F277 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 F293 - - - - - - T - - - G - - - - - K93R 
Prototype-like F488 - -
HK-3 F501 - - T - - C G - - A - - IC93R,N122K 
HK-11 F645 - T - - C G - - - - - IC93R 
HK-4 F646 G - - - - - - - - - T A - - G - - - - - I26V, K93R 
HK-1 F686 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 F706 - T - - - G - - - K93R 
HK-1 F720 - - - - - - T - - - G - - - - - K93R 
HK-1 F737 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 F764 - - - - - T - - - G K93R 
HK-4 F772 G - - - - - - - T A - - G - - - I26V, K93R 
HK-1 Q0028 - - - - - - - - - - - T - - - G K93R 
HK-1 Q0206 - - - - - T - - - G - - - - IC93R 
HK-1 Q0301 - - - - - - - - - - - T - - - G IC93R 
HK-1 Q0413 - - - - - T - - - G - - - - K93R 
HK-1 Q0436 - - - - - - T - - - G K93R 
HK-14 Q0582 - G T - - - G - - - - - K93R 
HK-1 Q0623 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 Q0730 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 Q0871 - - - - - - T - - - G - - - - - K93R 
HK-1 Q1152 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 Q1153 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-15 Q1324 C - T - - G - - - - K93R 
HK-1 Q1359 - - - - - - T - - - G IC93R 
HK-17 Q1399 G - - - T - - - G - - - - - K93R 
HK-1 Q1513 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 Q1533 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 Q1825 T - - - G K93R 
HK-6 Q1883 - - - - - - - - - - - T G -
HK-3 Q1907 T - - C G - - A - - K93R.N122K 
HK-1 Q2267 T - - - G - - - - - K93R 
HK-2 ST035 T A - - G - - - - - K93R 
Prototype-like ST048 - - - - - - - - - - - - - - -
HK-1 ST225 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-2 ST515 - - - - - - - - - - - T - - - G IC93R 
HK-1 W08142 - T - - - G - - - - - K93R 
HK-1 W08252 - T - - - G K93R 
HK-1 W08267 - - - - - - - - - - - T - - - G - - - - - K.93R 
Prototype-like W08376 - - - - - - -
HK-2 W08561 T A - - G - - - - - K93R 
HK-1 W08626 - T - - - G - - - - - K93R 
HK-1 W08780 - T - - - G - - - - - K-93R 
A 
HK-1 W08935 - - - - - I - - - I I T - - - G - - I I - K 9 3 R 
HK-1 W08957 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-16 W09267 - - - - - - G - - - - - K93R 
HK-1 W10345 - T - - - G K93R 
HK-1 W10436 - T - G - - - K93R 
HK-1 W10538 - - - - - - T - - - G K93R 
HK-1 WBX()160 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-3 WBXOIM T - - C G - - A - - IC93R,N122K 
HK-1 WBX0378 T - - - G K93R 
HK-1 WBX0504 - - - - - - - - - - - T • - - - G - - - - - K93R 
HK-2 WBX0656 T A - - G - - - - - K93R 
HK-2 WBX0920 T A - - G - - - - - K93R 
HK-18 WBX()928 T - - - - - - - G G 
HK-1 WBX()987 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 WBXI345 T - - - G - - - - - K93R 
HK-1 WS0008 T - - - G - - - - - K93R 
HK-1 WSOOlO - - - T - - - G - - - - - K93R 
HK-1 WS0035 T - - - G K93R 
HK-1 WS0036 - - - - - T - - G - - - - - K93R 
Prototype-like WS0045 - - - - - - - - - - - - - - - - - - - - -
Protot\pe-like WS0061 - - - - - - - - -
HK-1 WS0070 - - - - - - T - - - G - - - - - K93R 
HK-1 WS0075 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 WS0081 - T - - - G - - - - - K93R 
HK-7 WS0092 T - - - - - T - - - G C - - - -
HK-1 WS0096 - - - - - - - - - - - T - - - G K93R 
HK-12 WS0098 T - - - - - - - - -
HK-1 WS0104 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 WS0133 - - - - - T - - - G K93R 
HK-1 WS0148 T - - - G - - - - - K93R 
HK-13 WS0150 C - - - - - T - - - G K93R 
HK-1 WS0158 - - - - - T - - - G - - - - - K93R 
HK-9 WS0192 T - - - G C - - - - K93R, S97T 
HK-3 WS0203 T - - C G - - A - - !C93R,N122K 
Prototype-like WS0238 -
HK-1 WS0245 T - - - G - - - - - IC93R 
HK-1 WS0251 - T - - - G K93R 
HK-1 WS0280 T - - - G - - - - - K93R 
HK-8 WS0284 T - - - - - T G 
HK-1 WS0285 - T - - - G - - - - - K93R 
HK-10 WS0304 - - - - - T - - - G - G - - - K93R 
HK-1 WS0305 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 WS0346 - - - - - T - - G - - - - - K93R 
HK-1 WS0347 - - - - - - T - - - G - - - - - K93R 
HK-2 WS0465 T A - - G - - - - - K93R 
HK-1 WS0478 - - - - - T - - - G - - - - - K93R 
HK-1 WS0480 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-l WS0757 - - - - - - - - - - - T - - - G - - - - - K93R 
Protot>pe-Uke WS0820 - - - - - - - -
HK-1 WS0836 - T - - - G - - - - - K93R 
HK-1 WS0847 - T - - - G K93R 
HK-1 WS0848 - - - - - T - - - G - - - - - K93R 
HK-1 WS0859 - - - - T - - - G K93R 
HK-1 WS0875 - - - - - - - - - - - T - - - G K93R 
HK-1 WS0899 - - - - - - T - - - G K93R 
HK-1 WS09097 - - - - - - T - - - G - - - - K93R 
HK-1 WS0943 - - - - - - T - - - G K93R 
Prototype-like WS1043 - - - - - - -
HK-2 WS1045 T A - - G - - - - - K93R 
HK-2 WSllOl T A - - G - - - - - K93R 
HK-1 WS1144 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 WS1168 - - - - - T - - - G - - - - - K93R 
HK-1 WS1187 - T - - - G - - - - - K93R 
HK-5 WS1237 - C - - - T - - C G - - A - - K93R,N122K 
HK-1 WS1240 - - - T - - - G - - - - K93R 
HK-1 WS1241 - - - - - - - - - - - T - - - G IC93R 
HK-1 WS1244 - - - - - T - - - G - - - - - K93R 
HPV52 prototype (GenBank accession no. X74481) as reference. Nucleotide positions are written vertically across 
the top. Positions at which no variations were found are marked with dashes, a normal letter indicates a 
synonymous substituion and a bold letter represents a non-synonymous substitution. The one letter amino acid 
code is used. Position of amino acid changes are stated numerically. The letter preceding this number refers to the 
reference amino acid, and the letter following refers to its substitution. 
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Appendix II: 
Nucleotide and amino acid substitutions at E7 open reading frame of all Hong 
Kong isolates 
HK-2 0556T T A - - G K93R 
HK-1 0607T - - T - - G K93R 
Prototype-like 11 PA - - - - - - - - - -
Prototype-like 43 PA - - - - - - - - - - -
Prototype-like 45PA -
HK-1 55PA T - - - G - - - - - K93R 
HK-1 9048T T - - - G K93R 
Prototype-like AR310 -
HK-1 C198T T - - - G K93R 
HK-1 C210T - T - - - G K93R 
Prototype-like CN55 - - - - - - - - - - - - - - - -
non-HK-2 D056 G G - - - - - K93R 
HK-1 D357 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 F406 - - - - - T - - - G - - - - - K93R 
HK-1 F440 T - - - G K93R 
HK-1 F744 - T - - - G - - - - - K93R 
HK-6 K04 - - - - - - - - - - - T - - - - - - - G -
HK-1 K09 - - - - - - - - - - - T - - - G - - - - - K93R 
HK-1 KIO - - T - - G - - - - - K93R 
non-HK-4 K15 - A - - T - - - G K93R 
HK-1 K27 - - - - - - T - - - G K93R 
HK-1 K28 - - - - - T - - - G - - - - - K93R 
HK-1 K32 T - - - G - - - - - K93R 
HK-1 K35 T - - - G K93R 
HK-1 K47 - T - - - G - - - - K93R 
HK-1 K48 T - - - G K93R 
HK-1 K49 - T - - - G K93R 
HK-1 K51 - - - - - - T - - - G K93R 
HK-1 K55 - T - - - G K93R 
HK-1 K59 - - - - - T - - - G K93R 
HK-1 K60 - T - - G K93R 
non-HK-3 K61 T - A - G K93R 
HK-1 K67 T - - - G - - - - - K93R 
Prototype-like K69 -
HK-1 K70 T - - - G K93R 
HK-1 K74 T - - - G - - - - - K93R 
HK-1 K75 T - - - G - - - - - K93R 
Prototype-like P0098 - - - - -
HK-6 P0196 T - G -
Prototype-like P0419 - - - - - -
Non-HK-1 P0754 G - - - H24D 
non-HK-1 P1536 G - H24D 
Prototype-like PI 850 -
Prototype-like PI 897 -
Prototype-like P1952 -
HPV52 prototype (GenBank accession no. X74481) as reference. Nucleotide positions are written vertically across 
the top. Positions at which no variations were found are marked with dashes, a normal letter indicates a synonymous 
substituion and a bold letter represents a non-synonymous substitution. The one letter amino acid code is used. 
Position of amino acid changes are stated numerically. The letter preceding this number refers to the reference amino 
acid, and the letter following refers to its substitution. 
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Appendix III: 
Nucleotide and amino acid substitutions at E7 open reading frame of all Hong 
Kong isolates 
(y, ；y. •J-. C-, fy. a �_i 、•； � j -- : � j �J -J -J OC OC .00 oc 
� i » vn •、及 ‘.> j：^  Xi. (/< t f , t � » o J. 
E7 Variant Sp. No. 一 •-二 s^ i 工 r � 二 & <?、 二 < 一 oc o — 二 •r- o 广二；:、.„..… 
Prototvpe A T C C A A A A C T C C A A C C A A A T T 
HK-1 C342 T - - G - - -
HK-1 C361 - - - - - T - - G - - -
HK-1 C592 T - - G - - -
HK-1 C596 - - " - - T - - G - - -
HK-1 C623 T - - G - - -
HK-1 C644 丁 - - G - - -
HK-1 C847 - - - - - T - - G - - -
HK-1 C849 T - - G - - -
HK-1 C854 - - - T - - G - - -
HK-1 FOll - - - - - - - - - T - - G - - -
HK-1 F036 T - - G - - -
HK-1 F057 - - - - - T - - G - - -
HK-1 F082 - - - - - T - - G - - -
HK-1 F088 T - - G - - -
Prototype-like F095 
HK-1 F099 - - T - - G - - -
HK-1 F130 T - - G - - -
HK-1 F157 - - T - - G - - -
HK-1 F204 - - - - - - - - - - - - - - T - - G - - -
HK-1 F205 T - - G - - -
HK-1 F231 T - - G - - -
HK-1 F248 T - - G - - -
HK-1 F277 T - - G - - -
HK-1 F293 T - - G - - -
Prototype-like F488 -
HK-1 F501 T - - G - - -
HK-1 F645 T - - G - - -
HK-1 F646 - - - - - - T - - G - - -
HK-1 F686 T - - G - - -
HK-1 F706 T - - G - - -
HK-1 F720 T - - G - - -
HK-1 F737 T - - G - - -
HK-1 F764 T - - G - - -
HK-1 F772 T - - G - - -
HK-1 Q0028 - - - - - T - - G - - -
HK-1 Q0206 - - - - T - - G - - -
- A T p . p T A r r T37I, S52D, Y59D, H61Y, 
HK-2 Q0301 - A - - T - - G A G T A - - - - - G - - G d64n L99R 
HK-1 Q0413 T - - G - - -
HK-1 Q0436 T - - G - - -
HK-1 Q0582 T - - G - - -
HK-1 Q0623 - - T - - G - - -
HK-1 Q0730 - - - T - - G - - -
HK-1 Q0871 - T - - G - - -
HK-1 Q1152 T - - G - - -
Prototype-like Q1153 - -
HK-1 Q1324 T - - G - - -
HK-1 Q1359 T - - G - - -
HK-1 Q1399 T - - G - - -
HK-1 Q1513 - - - T - - G - - -
HK-1 Q1533 - - - - - - - - - - - - - - T - - G - - -
HK-1 Q1825 - - - - - T - - G - - -
HK-2 Q1883 - A - - T - - G A G T A G - - G 
HK-1 Q1907 - - - - - - - - - - - - - - T - - G - - -
HK-1 Q2267 - T - - G - - -
HK-1 ST035 - - - T - - G - - -
Prototype-like ST048 
HK-1 ST225 T - - G - - -
HK-1 ST515 T - - G - - -
HK-6 W08,42 G - C - - C T G T - - C - G C - K / ^ J f 8D，T66A， 
HK-1 W08252 T - - G - - -
HK-1 W08267 T - - G - - -
Prototype-like W08376 
HK-1 W08561 T - - G - - -
HK-1 W08626 T - - G - - -
F 
(•A Ui On O. O • � … < - < -J �J 乂 父 
E7-Vanant Sp No — i^ j «> oi os -j -j &o o — -i- <>0 — j- o 丨'tuliu。(.J ⑴丨im<, "ud 
siil)stUu(ion 
HK-1 W08780 - I ~ I I ~ I I I I ~ ~ I I I I I I T I - G I I I 
HK-1 W08935 T - - G - - -
HK-1 W08957 T - - G - - -
HK-1 W09267 T - - G - - -
HK-1 W10345 T - - G - - -
HK-1 W10436 T - - G - - -
HK-1 W10538 T - - G - - -
HK-1 WBX0160 - T - - G - - -
HK-1 WBX0164 T - - G - - -
HK-1 WBX0378 T - - G - - -
HK-1 WBX0504 T - - G - - -
HK-1 WBX0656 T - - G - - -
HK-1 WBX0920 - - T - - G - - -
OK 9 WRYficnji A ^ . „ „ . p p T37I, S52D, Y59D, H61Y, 
HK-2 WBX0928 - A - - T - - G A G T A u - - G D64N L99R 
HK-1 WBX0987 T - - G - - -
HK-1 WBX1345 T - - G - - -
HK-3 WS0008 T A - G - - -
HK-1 WSOOlO - - T - - G - - -
HK-1 WS0035 - - - - T - - G - - -
HK-1 WS0036 T - - G - - -
Prototype-like WS0045 
Prototype-like WS0061 
HK-1 WS0070 T - - G - - -
HK-1 WS0075 T - - G - - -
HK-1 WS0081 T - - G - - -
HK-4 WS0092 - - - T - T - - G - - -
HK-1 WS0096 T - - G - - -
HK-2 WS0098 - A - - T - - G A G T A G - - G ； 
HK-5 WS0104 - C T - - G - - -
HK-1 WS0133 T - - G - - -
HK-1 WS0148 丁 - - G - - -
HK-1 WS0150 T - - G - - -
HK-1 WS0158 - T - - G - - -
HK-4 WS0192 - - - T T - - G - - -
HK-1 WS0203 T - - G - - -
Prototype-like WS0238 - - -
HK-1 WS0245 T - - G - - -
HK-1 WS0251 T - - G - - -
HK-1 WS0280 T - - G - - -
HK-2 WS0284 - A - - T - - G A G T A G - - G 
HK-1 WS0285 T - - G - - -
HK-1 WS0304 T - - G - - -
HK-1 WS0305 T - - G - - -
HK-1 WS0346 T - - G - - -
HK-1 WS0347 - - - - T - - G - - -
HK-1 WS0465 T - - G - - -
HK-1 WS0478 T - - G - - -
HK-1 WS0480 T - - G - - -
HK-1 WS0757 T - - G - - -
Prototype-like WS0820 
HK-1 WS0836 T - - G - - -
HK-1 WS0847 - - - T - - G - - -
HK-1 WS0848 T - - G - - -
HK-1 WS0859 T - - G - - -
HK-1 WS0875 T - - G - - -
HK-1 WS0899 T - - G - - -
HK-1 WS0943 - - - - - T - - G - - -
HK-1 WS0997 T - - G - - -
Prototype-like WS1043 
HK-1 WS1045 T - - G - - -
HK-1 WSllOl T - - G - - -
HK-1 WS1144 T - - G - - -
HK-1 WS1168 - T - - G - - -
HK-1 WS1187 - - - T - - G - - -
HK-1 WS1237 T - - G - - -
HK-1 WS1240 T - - G - - -
HK-1 WS1241 T - - G - - -
HK-1 WS1244 T - - G - - -
HPV52 prototype (GenBank accession no. X74481) as reference. Nucleotide positions are written vertically across 
the top. Positions at which no variations were found are marked with dashes, a normal letter indicates a synonymous 
substitution and a bold letter represents a non-synonymous substitution. The one letter amino acid code is used. 
Position of amino acid changes are stated numerically. The letter preceding this number refers to the reference amino 
acid, and the letter following refers to its substitution. 
B 
Appendix IV: 
Nucleotide and amino acid substitutions at E7 open reading frame of all Hong 
Kong isolates 
�.l � j 、：） vo O^  �� O O K) 0> -tv - J O — i • , „ 
E7 Variant Sp No — — Prcoivicti /u—i: 
Piototjpc A T C C A A A A G T C G A A C C A A A T T 
HK-1 0556T T - - G - - -
HK-1 0607T T - - G - - -
Prototype-like 11 PA -
Prototype-like 43 PA - - -
Prototype-like 45PA 
HK-1 55PA T - - G - - -
HK-1 9048T T - - G - - -
Prototype-like AR310 
HK-1 C198T T - - G - - -
HK-1 C210T - - - T - - G - - -
Prototype-like CN55 - - - - -
HK-1 D056 T - - G - - -
HK-1 D357 T - - G - - -
HK-1 F406 T - - G - - -
HK-1 F440 - - - T - - G - - -
HK-1 F744 - - - - 丁 - - G - - -
HK-1 KIO - - - - T - - G - - -
HK-1 K15 - T - - G - - -
HK-1 K27 - - - - T - - G - - -
HK-1 K28 T - - G - - -
HK-1 K32 T - - G - - -
HK-1 K35 丁 - - G - - -
HK? K4 A T r A r T A G �T37I，S52D’ Y59D’ H61Y’ 
HK.-2 - A - - I - - (j A G I A D64N L99R 
HK-1 K47 T - - G - - -
HK-1 K48 - T - - G - - -
HK-1 K49 T - - G - - -
HK-1 K51 - T - - G - - -
HK-1 K55 T - - G - - -
HK-1 K59 T - - G - - -
HK-1 K60 - - T - - G - - -
HK-1 K61 丁 - - G - - -
HK-1 K67 T - - G - - -
Prototype-like K69 - -
HK-1 K70 丁 - - G - - -
HK-1 K74 T - - G - - -
HK-1 K75 T - - G - - -
HK-1 K9 T - - G - - -
Prototype-like P0098 
HK-2 P0196 - A - - T - - G A G T A G - - G _ Y’ 
Prototype-like P0419 
Prototype-like P0754 -
Prototype-like PI 536 
Prototype-like P1850 - - - - - - - -
Prototype-like PI 897 
Prototype-like PI 952 
HPV52 prototype (GenBank accession no. X74481) as reference. Nucleotide positions are written vertically across 
the top. Positions at which no variations were found are marked with dashes, a normal letter indicates a synonymous 
substitution and a bold letter represents a non-synonymous substitution. The one letter amino acid code is used. 
Position of amino acid changes are stated numerically. The letter preceding this number refers to the reference amino 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































c c c c c c c c c c c c c c c c c c c c 
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T T T T T T T T T T T T T T T 





























































































































































































































































































































































































































































































































































































































































































Nucleotide and amino acid substitutions at LCR open reading frame of all Hong 
Kong isolates 





























































































































































































































































































































































































































































































































































































































A C A 
































Protot,pr TAT G C G A 
C3420CC 
C)61 0 C 



































G C C 
Gce 
G c C 





G c C 
G C C 
G C 
G C 
G C C 





G c C 
G C C 
F737 0 C C 
F764 0 C 
F772 G C 
Q0028 0 C 




00582 G C 
00623 G C 
00730 G C 
Q0871 0 C 
QII52 Gce 
QII53 G C C 
QI324 G C 
Q\359 G C 
Q\399 0 C C 
QI513 0 C C 








ST515 0 C C 
W8142 
W8252 0 C C 
W8267 G C C 
W8376 








































































































































































































WBXI60 G C 






WBX987 G C C 
WBX1345 G C 
WSOOR C C 





WS070 G C C 
WS075 GCe 
WS081 Gce 
WS092 C C C 
WS096 G C 
WS098 G 
WSI04 Gce 
WS133 G C C 
WS148 Gce 
WSl50 G C 
WS158 G C 
WSI92 C C C 
WS203 GCCA 
WS238 






WS305 G C C 
WS346 G C 
WS347 G C 
WS465 Gce 
WS478 Gce 






WS859 G C C 
WS875 Gce 
WS899 G C C 
WS943 G C 







WSl237 G C 



































































































































































































































c . C • 
C • 
C • 
HPV52 prototype (GenBank accession no. X74481) as reference. Nucleotide positions are written vertically 
across the top. Positions at which no variations were found are marked with dashes, a nonnal letter indicates a 
synonymous substitution and a bold letter represents a non-synonymous substitution. The one letter amino acid 
code is used. Position of amino acid changes are stated numerically. The letter preceding this number refers to the 






Nucleotide and amino acid substitutions at LCR open reading frame of all 
overseas isolates 
~ ~ &i ~ ;j ii ~ ~ &: ~ ~ § § ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ § - ~ N ~ 
LCR Variant Sp. No. 
Prolotypr C C T T G '1 G CTCT G C A TG C G TIATG T G T C G A C A G A G G A G 
HK-3 0556T dol T dcl 
HK-I 0601T A dcl d,1 A 
HK-5 I IPA dol 
HK-9 43PA dcl 
non-HK-2 45PA d,1 
non-HK-3 55PA A d,1 d,1 
non-HK-4 9048T A d,1 d,1 
HK-5 AR3 10 d,1 
HK-16 Cl 9KT dO d,1 A 
HK-7 C210T A d. d,1 A 
HK-S CNSS d,1 
non-HK-S 0056 A A G G T A d,1 
HK·I 0357 d,1 d,1 
HK-1O F406 A d,1 T dcl 
HK-2 F440 A dcl T dcl 
HK-6 F144 A d,1 T d,1 
non-HK-8 KO. dol A 
HK-S2 K09 d,1 d,1 A 
HK-I KIO dol d,1 A 
HK-17 KI5 A dcl dcl 
HK-l K21 C dcl dcl 
non-HK-6 K28 C d,1 A dcl dcl A 
non-HK-7 K32 d,1 d,1 A A 
HK-2 105 d,1 d,1 
HK-2 K41 d,1 d,1 
HK·12 K48 A d,1 d,1 A 
HK-6 K49 A d,1 d,1 
HK-I K51 A dcl dol 
HK-I K55 d,1 d,1 
HK·I K59 dcl d,1 
HK-6 K60 dcl T d,1 
HK-2 K61 A dcl d,1 
HK-6 K61 A d,1 d. 
non-HK-9 K69 d,1 
HK·6 K10 d,' dcl A 
HK-l K14 d,' d,1 
HK-J K15 dcl d,1 
Prototype-like P0098 
non-HK-IO 1'0196 dcl A 
HK-5 P0419 d,1 
non-HK-I P0754 d,' 
non-HK-l 1'1536 d,1 
non-HK-ll PI850 dol 
ACTATGTGTI 




~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ !! ~ ~ ~ ~ ~ ;;: ~ <: ::; :;; ::: ~ 
" 
;: 
N ~ I; ~ ~ 
Sp. No. 
PrOlOlype T A T G C G A Ten' G G C T A G A G T A G A G C ., T A A T T A T A T T A 
0556T G C C dd C G 




55PA C C d,' C G G 
9048T G C C dol C G G 
AR310 
CI98T G C C del C G G 
C210T G C C d,' C G 
CN55 
0056 d,' T C 
0357 G C C d,' G G 
F406 G C C dol A G G C 
F44D G C C d,' C A G C G C 
F744 G C C d,' A G 
KO. G C T A C d,' G A A 
KO. G C C d" C G 
K'O G C C d,' C A G G 
KIS G C C d,' C A A G C G 
K27 G C C d,' C G G 
1028 G C dol C A G A 
K32 G C d,' C A G 
105 G C C d,' C A G C G 
K47 G C C dd C A G C G 
K48 G C C d,' A G 
K49 G C C d,' G 
10' G C C d,' C G G 
105 G C C d,' G G 
KS9 G C C d" A G G 
KW G C C d,' C A G 
K6I G C C d,' G C G 
K67 G C C d,' A G 
K69 
K70 G C C d,' C G 
K74 G C d,' C A G C G 
K75 G C d,' C A G G 
P0098 







HPV52 prototype (GenBank accession no. X7448 I) as reference. Nucleotide positions are written vertically 
across the top. Positions at which no variations were found are marked with dashes, a normal letter indicates a 
synonymous substitution and a bold letter represents a non-synonymous substitution. The one letter amino acid 
code is used. Position of amino acid changes are stated numerically. The letter preceding this number refers to the 
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0 0446 1330 
